<doc>
  <docmeta id="113hr1919ih">
    <bill congress="113" type="hr" number="1919" version="ih"/>
    <revision size="129254" annotations="0" status="complete" id="5" commit-time="2013-09-03T20:04:13Z" committer="mbohmer" doc="113hr1919ih/5.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HB830F70FF7E04CC7932F2128960E6408" public-private="public">
	<metadata>
<dublinCore>
<title>113 HR 1919 IH: Safeguarding America’s Pharmaceuticals Act of 2013</title>
<publisher>U.S. House of Representatives</publisher>
<date>2013-05-09</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 1919</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130509">May 9, 2013</action-date>
			<action-desc>
        <sponsor name-id="L000566">Mr. Latta</sponsor> (for
			 himself, <cosponsor name-id="M001142">Mr. Matheson</cosponsor>,
			 <cosponsor name-id="U000031">Mr. Upton</cosponsor>,
			 <cosponsor name-id="D000355">Mr. Dingell</cosponsor>,
			 <cosponsor name-id="C001075">Mr. Cassidy</cosponsor>,
			 <cosponsor name-id="B001243">Mrs. Blackburn</cosponsor>,
			 <cosponsor name-id="M001180">Mr. McKinley</cosponsor>,
			 <cosponsor name-id="R000572">Mr. Rogers of Michigan</cosponsor>,
			 <cosponsor name-id="B001248">Mr. Burgess</cosponsor>,
			 <cosponsor name-id="S000364">Mr. Shimkus</cosponsor>,
			 <cosponsor name-id="G000558">Mr. Guthrie</cosponsor>,
			 <cosponsor name-id="J000292">Mr. Johnson of Ohio</cosponsor>, and
			 <cosponsor name-id="S001190">Mr. Schneider</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act with
		  respect to the pharmaceutical distribution supply chain, and for other
		  purposes.</official-title>
	</form>
	<legis-body id="H3854716CC3BD4827AEEA45A0EC9DA031" style="OLC">
		<section id="H72C655D1DEDF48A89660F5D167049E39" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
			<subsection id="HD35D80F3D4954E338A99E778C4151CB0">
        <enum>(a)</enum>
        <header>Short
			 title</header>
        <text display-inline="yes-display-inline">This Act may be cited
			 as the <quote>
            <short-title>Safeguarding America’s
			 Pharmaceuticals Act of 2013</short-title>
          </quote>.</text>
			</subsection>
      <subsection id="H1D5A2670DB554367B8F5FA0B54CF3C50">
        <enum>(b)</enum>
        <header>Table of
			 contents</header>
        <text display-inline="yes-display-inline">The table of
			 contents of this Act is as follows:</text>
				<toc container-level="legis-body-container" lowest-bolded-level="division-lowest-bolded" lowest-level="section" quoted-block="no-quoted-block" regeneration="yes-regeneration">
					<toc-entry idref="H72C655D1DEDF48A89660F5D167049E39" level="section">Sec. 1. Short title.</toc-entry>
					<toc-entry idref="HB357B67CD5F5450F8C086AE1812537EE" level="section">Sec. 2. Pharmaceutical distribution supply chain.</toc-entry>
					<toc-entry idref="H801E4EA5B0CE4E55A5615C152565C568" level="section">Sec. 3. Enhanced drug distribution security.</toc-entry>
					<toc-entry idref="HBC811089AEF040D7BD190C77C6C8F710" level="section">Sec. 4. National standards for wholesale
				distributors.</toc-entry>
					<toc-entry idref="H02F1F3FBD44A4CEEB8AB35881F40C73A" level="section">Sec. 5. National licensure standards for third-party logistics
				providers.</toc-entry>
					<toc-entry idref="HBBE033AA9EFC4648B1362CE5C0B58FBA" level="section">Sec. 6. Penalties.</toc-entry>
					<toc-entry idref="HB08D8528E49B4FF2AF7AFB4085BBE032" level="section">Sec. 7. Uniform national policy.</toc-entry>
					<toc-entry idref="H3AA75D01CEC44FD3822CECB9C38A4019" level="section">Sec. 8. Electronic labeling requirement.</toc-entry>
				</toc>
			</subsection>
    </section>
    <section id="HB357B67CD5F5450F8C086AE1812537EE">
      <enum>2.</enum>
      <header>Pharmaceutical
			 distribution supply chain</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V">Chapter V of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/351">
            <cato:entity-ref entity-type="uscode" value="usc/21/351/etseq">21 U.S.C. 351 et seq.</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the
			 following:</text>
			<quoted-block display-inline="no-display-inline" id="HE375A5EEE7454232818925C3BDB9648F" style="OLC">
				<subchapter id="HE932F170967A452C8CE6315266C3EC0C">
          <enum>H</enum>
          <header>Pharmaceutical
				Distribution Supply Chain</header>
					<section id="HA873B3AAF53C4F53AB863DB8DB1ED690">
            <enum>581.</enum>
            <header>Definitions</header>
            <text display-inline="no-display-inline">In this subchapter:</text>
						<paragraph id="HDED5A2A8624049A79B7B489AED8F5CCC">
              <enum>(1)</enum>
              <header>Authorized</header>
              <text>The
				term <term>authorized</term> means—</text>
							<subparagraph id="H005240D3C667414B80B1B44B76F5F59D">
                <enum>(A)</enum>
                <text>in the case of a
				manufacturer or repackager, having a valid registration in accordance with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>; and</text>
							</subparagraph>
              <subparagraph id="H393127E7BEFE41F0A53379187415B237">
                <enum>(B)</enum>
                <text>in the case of a
				wholesale distributor, third-party logistics provider, or dispenser, licensed
				(as defined in this section).</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H2053ACDE11F14916AC3D89A69B608B3A">
              <enum>(2)</enum>
              <header>Dispenser</header>
              <text>The
				term <term>dispenser</term>—</text>
							<subparagraph id="H14F90E8614274345A3B3185A4ADB5248">
                <enum>(A)</enum>
                <text>subject to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>, means a retail pharmacy, hospital pharmacy, a group of chain
				pharmacies under common ownership and control that do not act as a wholesale
				distributor, or any other person authorized by law to dispense or administer
				prescription drugs and the affiliated warehouses or distribution centers of
				such persons under common ownership and control that do not act as a wholesale
				distributor; and</text>
							</subparagraph>
              <subparagraph id="H686EBCB4FDA9449BA83B2FA585575700">
                <enum>(B)</enum>
                <text>does not include a
				person who only dispenses prescription drug product to be used in animals in
				accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:a/p:5">section 512(a)(5)</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HD3527F860D9741A5A9C2269245271047">
              <enum>(3)</enum>
              <header>Disposition</header>
              <text>The
				term <term>disposition</term>, with respect to a prescription drug product
				within the possession and control of an entity—</text>
							<subparagraph id="H567343A935ED41738EC79B6A609F8426">
                <enum>(A)</enum>
                <text>means the removal
				of such prescription drug product, or taking measures to prevent the
				introduction of such prescription drug product, from the pharmaceutical
				distribution supply chain; and</text>
							</subparagraph>
              <subparagraph id="H6E39C9B172AC40859C4BEC072C444AF4">
                <enum>(B)</enum>
                <text>may include
				disposal, return of the prescription drug product for disposal, or other
				appropriate handling and other actions such as retaining a sample of the
				prescription drug product for additional physical examination or laboratory
				analysis by a manufacturer or regulatory or law enforcement agency.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H9A08FD0C683F4F11B4842E5377010FD7">
              <enum>(4)</enum>
              <header>Distribute or
				distribution</header>
              <text>The terms <term>distribute</term> and
				<term>distribution</term> mean the sale, purchase, trade, delivery, handling,
				or storage of a prescription drug product.</text>
						</paragraph>
            <paragraph id="H9B2AA0FEA1414F9981D2873E5B15C7E1">
              <enum>(5)</enum>
              <header>Illegitimate
				prescription drug product</header>
              <text>The term <term>illegitimate
				prescription drug product</term> means a prescription drug product which a
				manufacturer has confirmed—</text>
							<subparagraph id="HC8F182DEDF60476EA6A8227F2B63621B">
                <enum>(A)</enum>
                <text>is counterfeit,
				diverted, or stolen;</text>
							</subparagraph>
              <subparagraph id="H588BDD75CE744D2787BF50170CFBF66E">
                <enum>(B)</enum>
                <text>is intentionally
				adulterated such that the prescription drug product would result in serious
				adverse health consequences or death to humans; or</text>
							</subparagraph>
              <subparagraph id="H3A8C46B145D64AF0AE04E0974C548A6E">
                <enum>(C)</enum>
                <text>is otherwise unfit
				for distribution such that the prescription drug product is reasonably likely
				to cause serious adverse human health consequences or death.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HA0086E7B2B9C427E88A1EF9FA4C78EB6">
              <enum>(6)</enum>
              <header>Licensed</header>
              <text>The
				term <term>licensed</term> means—</text>
							<subparagraph id="H3C3A04F7B22249249340D25C5804DDEC">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">in the case of a wholesale distributor,
				having a valid license to make wholesale distributions consistent with the
				standards under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>;</text>
							</subparagraph>
              <subparagraph id="H528AD34525984A549E459D8D21E7AF0F">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">in the case of a third-party logistics
				provider, having a valid license to engage in the activities of a third-party
				logistics provider in accordance with section 584; and</text>
							</subparagraph>
              <subparagraph id="HCE8113BBD9514C0180A02B0B9F7467A5">
                <enum>(C)</enum>
                <text>in the case of a
				dispenser, having a valid license to dispense prescription drugs under State
				law.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HDC31C22DE9BC48E08E22E5A662455DA4">
              <enum>(7)</enum>
              <header>Manufacturer</header>
              <text>The
				term <term>manufacturer</term> means, with respect to a prescription drug
				product—</text>
							<subparagraph id="H554A018EDEB0481E8C833DA999116686">
                <enum>(A)</enum>
                <text>a person that
				holds an application approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or a license issued under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> for such prescription drug
				product, or if such prescription drug product is not the subject of an approved
				application or license, the person who manufactured the prescription drug
				product;</text>
							</subparagraph>
              <subparagraph id="HE020DD9FAF104BBEA6F96FB510DA607A">
                <enum>(B)</enum>
                <text>a co-licensed
				partner of the person described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> that obtains the
				prescription drug product directly from the person described in such
				subparagraph; or</text>
							</subparagraph>
              <subparagraph id="HB777DA937C2041CCB58ECA9136FAF867">
                <enum>(C)</enum>
                <text display-inline="yes-display-inline">a person that—</text>
								<clause id="HA9E3A2B59BD14185974D81EC7C4BA13A">
                  <enum>(i)</enum>
                  <text>is
				a member of an affiliated group (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1504/ss:a">section 1504(a) of the Internal
				Revenue Code of 1986</cato:entity-ref>) to which a person described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:B" proposed="true">(B)</cato:entity-ref> is
				also a member; and</text>
								</clause>
                <clause id="HFDDE2EF311D2438AAA3CDEA2C4C0B6A8">
                  <enum>(ii)</enum>
                  <text>receives the
				prescription drug product directly from a person described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>
				or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:B" proposed="true">(B)</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
            </paragraph>
            <paragraph id="H5505D74842754FE4A009A7608D3B408A">
              <enum>(8)</enum>
              <header>Package</header>
							<subparagraph id="HCCEAF3209FBA4BE9912356E90612D444">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text display-inline="yes-display-inline">The term
				<term>package</term> means the smallest individual saleable unit of
				prescription drug product for distribution in interstate commerce by a
				manufacturer or repackager that is intended by the manufacturer for ultimate
				sale to the dispenser of such prescription drug product.</text>
							</subparagraph>
              <subparagraph id="H7CD5FB1BC2CA45B49EDBFD3402710C29">
                <enum>(B)</enum>
                <header>Individual
				saleable unit</header>
                <text display-inline="yes-display-inline">The term
				<term>individual saleable unit</term> means the smallest container of
				prescription drug product introduced into interstate commerce by the
				manufacturer or repackager that is intended by the manufacturer for individual
				sale to a dispenser.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H59F8C95255DC43BA9B5CAD2ECE811718">
              <enum>(9)</enum>
              <header>Prescription
				drug</header>
              <text>The term <term>prescription drug</term> means a drug for
				human use subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="H0734D8F4628F469C9D9568355B50CC30">
              <enum>(10)</enum>
              <header>Prescription
				drug product</header>
              <text display-inline="yes-display-inline">The term
				<term>prescription drug product</term> means a prescription drug in a finished
				dosage form for administration to a patient without substantial further
				manufacturing (such as capsules, tablets, and lyophilized prescription drug
				products before reconstitution).</text>
						</paragraph>
            <paragraph id="HB450F3E2BB1049E39B2FF269DB7ACDAD">
              <enum>(11)</enum>
              <header>Prescription
				drug product identifier</header>
              <text>The term <term>prescription drug product
				identifier</term> means a standardized graphic that—</text>
							<subparagraph id="H7829ABBD73FE4750A2BAE9EF7C30C517">
                <enum>(A)</enum>
                <text>includes the
				standardized numerical identifier, lot number, and expiration date of a
				prescription drug product; and</text>
							</subparagraph>
              <subparagraph id="H5F624F25C2644E88A8CA0B89BE721609">
                <enum>(B)</enum>
                <text>is in both
				human-readable form and on a machine-readable data carrier that conforms to the
				standards developed by a widely recognized international standards development
				organization.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H1D89A77B389F4CBCB0F48B4A6AA11F0D">
              <enum>(12)</enum>
              <header>Quarantine</header>
              <text display-inline="yes-display-inline">The term <term>quarantine</term> means to
				store or identify a product, for the purpose of preventing distribution or
				transfer of the product, in a physically separate area clearly identified for
				such use, or through use of other procedures such as automated
				designation.</text>
						</paragraph>
            <paragraph id="H4CB1154B872D40CA831F706981BF8864">
              <enum>(13)</enum>
              <header>Repackager</header>
              <text>The
				term <term>repackager</term> means a person who owns or operates an
				establishment that repacks and relabels a prescription drug product or package
				for further sale or distribution.</text>
						</paragraph>
            <paragraph id="H63A189308B86410D83985D24BA3388DA">
              <enum>(14)</enum>
              <header>Return</header>
              <text>The
				term <term>return</term> means providing prescription drug product to the
				authorized trading partner or trading partners from which such prescription
				drug product was purchased, or to a returns processor for handling of such
				prescription drug product.</text>
						</paragraph>
            <paragraph id="H6D2907444D3D42AA860125486A6D5A63">
              <enum>(15)</enum>
              <header>Returns
				processor</header>
              <text>The terms <term>returns processor</term> mean a person
				who owns or operates an establishment that provides for the disposition of or
				otherwise processes saleable and nonsaleable prescription drug product received
				from an authorized trading partner such that the prescription drug product may
				be processed for credit to the purchaser, manufacturer, seller, or disposed of
				for no further distribution.</text>
						</paragraph>
            <paragraph id="H2A7B46595C7C41E1997DD6E949931C16">
              <enum>(16)</enum>
              <header>Specific
				patient need</header>
              <text>The term <term>specific patient need</term>—</text>
							<subparagraph id="HC796D25869314E63A9163D30E5DA88F1">
                <enum>(A)</enum>
                <text>means with respect
				to the transfer of a prescription drug product from one pharmacy to another, to
				fill a prescription for an identified patient; and</text>
							</subparagraph>
              <subparagraph id="H8875AF307F1440E08C6C47E6010A2127">
                <enum>(B)</enum>
                <text>does not include
				the transfer of a prescription drug product from one pharmacy to another for
				the purpose of increasing or replenishing stock in anticipation of a potential
				need.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H1FF1BBFC125142C8884B89BB5BA51D56">
              <enum>(17)</enum>
              <header>Standardized
				numerical identifier</header>
              <text display-inline="yes-display-inline">The term
				<term>standardized numerical identifier</term> means a set of numbers or
				characters that—</text>
							<subparagraph id="HE25F4A935B0044F8AEA0E61198E17368">
                <enum>(A)</enum>
                <text>is used to
				uniquely identify each package or homogenous case of the prescription drug
				product; and</text>
							</subparagraph>
              <subparagraph id="HEB6E48E169FD4F8797E5AFE24B18C64E">
                <enum>(B)</enum>
                <text>is composed of the
				National Drug Code that corresponds to the specific prescription drug product
				(including the particular package configuration) combined with a unique
				alphanumeric serial number of up to 20 characters.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H6E91226AE5F74190B52FD42415D05ED6">
              <enum>(18)</enum>
              <header>Suspect
				prescription drug product</header>
              <text>The term <term>suspect prescription
				drug product</term> means a prescription drug product for which there is reason
				to believe that such prescription drug product—</text>
							<subparagraph id="HBF055118BD3C4C7685B0DB42F36FCED5">
                <enum>(A)</enum>
                <text>is potentially
				counterfeit, diverted, or stolen;</text>
							</subparagraph>
              <subparagraph id="HD5B484BF273646309B97B7965DB0A931">
                <enum>(B)</enum>
                <text>is potentially
				intentionally adulterated such that the prescription drug product would result
				in serious adverse health consequences or death to humans; or</text>
							</subparagraph>
              <subparagraph id="H73F9FAA86ED0434F8AA219C6B882F6F7">
                <enum>(C)</enum>
                <text>appears otherwise
				unfit for distribution such that the prescription drug product would result in
				serious adverse health consequences or death to humans.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H454C18ACF6FA4A4E82893EF9CD7B8808">
              <enum>(19)</enum>
              <header>Third-party
				logistics provider</header>
              <text>The term <term>third-party logistics
				provider</term> means an entity that provides or coordinates warehousing,
				distribution, or other logistics services of a prescription drug product in
				interstate commerce on behalf of a manufacturer, wholesale distributor, or
				dispenser of a prescription drug product, but does not take ownership of the
				prescription drug product, nor have responsibility to direct the sale or
				disposition of, the prescription drug product.</text>
						</paragraph>
            <paragraph id="H544F7B0FE567417A8B1FB9D6CB81A081">
              <enum>(20)</enum>
              <header>Trading
				partner</header>
              <text>The term <term>trading partner</term> means—</text>
							<subparagraph id="H1CEE77E1D6504B37ACB194C17EA1B7AB">
                <enum>(A)</enum>
                <text>a manufacturer,
				repackager, wholesale distributor, or dispenser from whom a manufacturer,
				repackager, wholesale distributor, or dispenser accepts ownership of a
				prescription drug product or to whom a manufacturer, repackager, wholesale
				distributor, or dispenser transfers ownership of a prescription drug product;
				or</text>
							</subparagraph>
              <subparagraph id="H76DD7111BD734C3D9D94DA683AD8A07D">
                <enum>(B)</enum>
                <text>a third-party
				logistics provider from whom a manufacturer, repackager, wholesale distributor,
				or dispenser accepts possession of a prescription drug product or to whom a
				manufacturer, repackager, wholesale distributor, or dispenser transfers
				possession of a prescription drug product.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H3C9F332024A949D68D49C0BA9EFB2E54">
              <enum>(21)</enum>
              <header>Transaction</header>
							<subparagraph id="HCBB98395BF6E49A983C60F0C940B06E1">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>The term <term>transaction</term> means the transfer in
				interstate commerce of prescription drug product between persons in which a
				change of ownership occurs.</text>
							</subparagraph>
              <subparagraph id="HE9A77FF53E6B4B329C2688062B08CAAC">
                <enum>(B)</enum>
                <header>Exemptions</header>
                <text>The
				term <term>transaction</term> does not include—</text>
								<clause id="HE5359FBA2CAC4391B90978C47D7C16B6">
                  <enum>(i)</enum>
                  <text>intracompany
				distribution of any prescription drug product between members of an affiliated
				group (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1504/ss:a">section 1504(a) of the Internal Revenue Code of
				1986</cato:entity-ref>);</text>
								</clause>
                <clause id="H93C58B59124D4F8AA7F117130A1A17E0">
                  <enum>(ii)</enum>
                  <text>the distribution
				of a prescription drug product among hospitals or other health care entities
				that are under common control;</text>
								</clause>
                <clause id="HDD63A136F301451BB4B526B721EE5230">
                  <enum>(iii)</enum>
                  <text>the distribution
				of a prescription drug product for emergency medical reasons including a public
				health emergency declaration pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:319">section 319 of the Public Health
				Service Act</cato:entity-ref>, except that a drug shortage not caused by a public health
				emergency shall not constitute an emergency medical reason;</text>
								</clause>
                <clause id="HB31C91BC8044493F870C9103A6945735">
                  <enum>(iv)</enum>
                  <text>the dispensing of
				a prescription drug product pursuant to a valid prescription executed in
				accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>;</text>
								</clause>
                <clause id="HBE47E9E6B0C24BE0B620F0F03EB96FDB">
                  <enum>(v)</enum>
                  <text>the distribution
				of prescription drug product samples by a manufacturer or a licensed wholesale
				distributor in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:d">section 503(d)</cato:entity-ref>;</text>
								</clause>
                <clause id="H52A265866355478A97DE913D9DF831E4">
                  <enum>(vi)</enum>
                  <text>the distribution
				of blood or blood components intended for transfusion;</text>
								</clause>
                <clause id="HCE9D8DA34F214983905E8977DF4745FA">
                  <enum>(vii)</enum>
                  <text>the distribution
				of minimal quantities of prescription drug product by a licensed retail
				pharmacy to a licensed practitioner for office use;</text>
								</clause>
                <clause id="HE1A9EEF3A5244048BD2E8CDF2D9459B8">
                  <enum>(viii)</enum>
                  <text>the
				distribution of a prescription drug product by a charitable organization to a
				nonprofit affiliate of the organization to the extent otherwise permitted by
				law;</text>
								</clause>
                <clause id="H8A0B691073D24EF2B21D2C47F06ADB08">
                  <enum>(ix)</enum>
                  <text>the distribution
				of a prescription drug product pursuant to the sale or merger of a pharmacy or
				pharmacies or a wholesale distributor or wholesale distributors, except that
				any records required to be maintained for the prescription drug product shall
				be transferred to the new owner of the pharmacy or pharmacies or wholesale
				distributor or wholesale distributors;</text>
								</clause>
                <clause id="H79E9A38E068D4F77977648C9E5C0EE13">
                  <enum>(x)</enum>
                  <text>the dispensing of
				a prescription drug product approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b">section 512(b)</cato:entity-ref>;</text>
								</clause>
                <clause commented="no" id="H832E1E814A744C51BE4116172697B68E">
                  <enum>(xi)</enum>
                  <text>the transfer of
				prescription drug products to or from any facility that is licensed by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="3100">Nuclear Regulatory Commission</cato:entity-ref> or by a State pursuant to an agreement with such
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="3100">Commission</cato:entity-ref> under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Atomic Energy Act of 1954/s:274">section 274 of the Atomic Energy Act of 1954</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/2021">42 U.S.C.
				2021</cato:entity-ref>)</cato:entity>;</text>
								</clause>
                <clause commented="no" display-inline="no-display-inline" id="H1263B45BFFB84A92904350905E1E5D4A">
                  <enum>(xii)</enum>
                  <text>the distribution
				of a combination product that consists of—</text>
									<subclause commented="no" id="H765B2B58F5424BB8ACAD94C46DA290E8">
                    <enum>(I)</enum>
                    <text>a product
				comprised of two or more components that are each a drug, biological product,
				or device and that are physically, chemically, or otherwise combined or mixed
				and produced as a single entity;</text>
									</subclause>
                  <subclause commented="no" id="HFEE720537CF2457C918951B00E2F78C3">
                    <enum>(II)</enum>
                    <text>two or more
				separate products packaged together in a single package or as a unit and
				comprised of a drug and device or a device and biological product; or</text>
									</subclause>
                  <subclause commented="no" id="H87A66BAB0684462499211613192A0B7D">
                    <enum>(III)</enum>
                    <text>two or more
				finished devices plus one or more drug or biological products which are
				packaged together in a medical convenience kit described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:21/sp:B/cl:xiv" proposed="true">clause
				(xiv)</cato:entity-ref>;</text>
									</subclause>
                </clause>
                <clause id="HED335F5BB56D4433BB665FF868FBE655">
                  <enum>(xiii)</enum>
                  <text>the
				distribution of a medical convenience kit which is a collection of finished
				products (consisting of devices or drugs) assembled in kit form strictly for
				the convenience of the purchaser or user if—</text>
									<subclause id="H8FAA11A746D349C9A85FDA7338AB5869">
                    <enum>(I)</enum>
                    <text>the medical
				convenience kit is assembled in an establishment that is registered with the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> as a medical device manufacturer;</text>
									</subclause>
                  <subclause id="H3EAF11CEC2BE492B8ECF0D90F45AD946">
                    <enum>(II)</enum>
                    <text>the person who
				manufacturers the medical convenience kit purchased the prescription drug
				product directly from the manufacturer or from a wholesale distributor that
				purchased the prescription drug product directly from the manufacturer;</text>
									</subclause>
                  <subclause id="H29361991E4FE441EB69406AA1B3E892E">
                    <enum>(III)</enum>
                    <text>the person who
				manufacturers the medical convenience kit does not alter the primary container
				or label of the prescription drug product as purchased from the manufacturer or
				wholesale distributor;</text>
									</subclause>
                  <subclause id="HECAE977DFDD543B381F27308167101D4">
                    <enum>(IV)</enum>
                    <text>the medical
				convenience kit does not contain a controlled substance (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102">section
				102 of the Controlled Substances Act</cato:entity-ref>); and</text>
									</subclause>
                  <subclause id="H4433914BA6BB488EBA618620D5AB169F">
                    <enum>(V)</enum>
                    <text>the prescription
				drug products contained in the medical convenience kit are—</text>
										<item id="H64E6BC6092BD454093CE6008ACD51771">
                      <enum>(aa)</enum>
                      <text>intravenous
				solutions intended for the replenishment of fluids and electrolytes;</text>
										</item>
                    <item id="H5A284784E94B457FB8BE1898FB2CD485">
                      <enum>(bb)</enum>
                      <text>drugs intended to
				maintain the equilibrium of water and minerals in the body;</text>
										</item>
                    <item id="H63A044C4FC4042A7A264E54055A78D46">
                      <enum>(cc)</enum>
                      <text>drugs intended
				for irrigation or reconstitution;</text>
										</item>
                    <item id="H371024D6AC454A64A9747D24607978B0">
                      <enum>(dd)</enum>
                      <text>anesthetics;</text>
										</item>
                    <item id="HF273056F17C447E288A0E4400A508B7A">
                      <enum>(ee)</enum>
                      <text>anticoagulants;</text>
										</item>
                    <item id="HAD4979CBE0D741968D3C9E08D3283429">
                      <enum>(ff)</enum>
                      <text>vasopressors;
				or</text>
										</item>
                    <item id="HDFC58E5353224050840C4E8AD690728C">
                      <enum>(gg)</enum>
                      <text>sympathicomimetics;</text>
										</item>
                  </subclause>
                </clause>
                <clause id="H1F2D9B3CB4C343CDB6FDBB1D7F34DA28">
                  <enum>(xiv)</enum>
                  <text>the distribution
				of an intravenous prescription drug product that, by its formulation, is
				intended for the replenishment of fluids and electrolytes (such as sodium,
				chloride, and potassium) or calories (such as dextrose and amino acids);</text>
								</clause>
                <clause id="H79C5122F95B743768AF165C9A19F4012">
                  <enum>(xv)</enum>
                  <text>the distribution
				of an intravenous prescription drug product used to maintain the equilibrium of
				water and minerals in the body, such as dialysis solutions;</text>
								</clause>
                <clause id="HEEE1BAAEECEF4CE7AC7A5A35FFEF7ABD">
                  <enum>(xvi)</enum>
                  <text>the distribution
				of a prescription drug product that is intended for irrigation or
				reconstitution, or sterile water, whether intended for such purposes or for
				injection; or</text>
								</clause>
                <clause id="HFF3D1E459BE7470D94CDF9B8F173E883">
                  <enum>(xvii)</enum>
                  <text>the
				distribution of compressed medical gas.</text>
								</clause>
              </subparagraph>
              <subparagraph id="H553C9BBDEC144E7C830DD9891D3FCC8F">
                <enum>(C)</enum>
                <header>Compressed
				medical gas</header>
                <text>For purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:21/sp:B/cl:xviii" proposed="true">subparagraph (B)(xviii)</cato:entity-ref>, the term
				<term>compressed medical gas</term> means any substance in its gaseous or
				cryogenic liquid form that meets medical purity standards and has application
				in a medical or homecare environment, including oxygen and nitrous
				oxide.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HD1B757E6EF584088AE8521BEB6DE7053">
              <enum>(22)</enum>
              <header>Transaction
				history</header>
              <text>The term <term>transaction history</term> means a
				statement that—</text>
							<subparagraph id="H8D838B39CCAC46BBB4078332388208FC">
                <enum>(A)</enum>
                <text>includes the
				transaction information for each transaction conducted with respect to a
				prescription drug product beginning with the manufacturer or initial purchase
				distributor for each prior transaction going back to the manufacturer of the
				prescription drug product or to the initial purchase distributor; and</text>
							</subparagraph>
              <subparagraph id="H3F0A0311410E4AB58D2728B10772B745">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">is in paper or electronic form.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HDE6DF18B448245C4938B1A35B9980BFF">
              <enum>(23)</enum>
              <header>Transaction
				information</header>
              <text>The term <term>transaction information</term>
				means—</text>
							<subparagraph id="HD664BFA70D584C508BA75545FFB3EEDF">
                <enum>(A)</enum>
                <text>the proprietary or
				established name or names of the prescription drug product;</text>
							</subparagraph>
              <subparagraph id="H2A04CFFAD47F4D07A6DF4B8E60A8AB01">
                <enum>(B)</enum>
                <text>the strength and
				dosage form of the prescription drug product;</text>
							</subparagraph>
              <subparagraph id="HEB8ED6127D7F4ACC9F99B60B03CC0D67">
                <enum>(C)</enum>
                <text>the National Drug
				Code number of the prescription drug product;</text>
							</subparagraph>
              <subparagraph id="H7FDE85F634274F0C8672F6A335F2ADB9">
                <enum>(D)</enum>
                <text>the container
				size;</text>
							</subparagraph>
              <subparagraph id="HC2F60D2C67E4409BB33E78C5552405CE">
                <enum>(E)</enum>
                <text>the number of
				containers;</text>
							</subparagraph>
              <subparagraph id="H7FA8FF6D03644EE8A159EDAA560896C8">
                <enum>(F)</enum>
                <text>the lot number of
				the prescription drug product;</text>
							</subparagraph>
              <subparagraph id="HB593E41A6E9A481DACF096E628E957CC">
                <enum>(G)</enum>
                <text>the date of the
				transaction;</text>
							</subparagraph>
              <subparagraph id="H1BA777CA89E14E12BF7BACE97F82D0C6">
                <enum>(H)</enum>
                <text>the business name
				and address of the person from whom ownership is being transferred; and</text>
							</subparagraph>
              <subparagraph id="H3FE2F07AAA9B47FAA705518053B330F5">
                <enum>(I)</enum>
                <text>the business name
				and address of the person to whom ownership is being transferred.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HE333052B0374446CA2068F43B9156DDE">
              <enum>(24)</enum>
              <header>Transaction
				statement</header>
              <text>The <quote>transaction statement</quote> is a
				statement, which states that the manufacturer, repackager, wholesale
				distributor, third-party logistics provider, or dispenser transferring
				ownership in a transaction—</text>
							<subparagraph id="H13B1B2F8FA2040FD9231EAE7573AA073">
                <enum>(A)</enum>
                <text>is
				authorized;</text>
							</subparagraph>
              <subparagraph id="H8714620C929041518AF6E1FA1203C03F">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">received transaction information and a
				transaction statement as required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref> from the prior owner of the
				prescription drug product;</text>
							</subparagraph>
              <subparagraph id="H8AE11A570808493A8E26FEA5C00AD9C3">
                <enum>(C)</enum>
                <text>did not knowingly
				and intentionally ship an illegitimate prescription drug product;</text>
							</subparagraph>
              <subparagraph id="H572DD39DC2D3408097E8622EA37CA034">
                <enum>(D)</enum>
                <text>did not knowingly
				and intentionally provide false transaction information; and</text>
							</subparagraph>
              <subparagraph id="H207DDC863A874F98B45B6DE4E4648247">
                <enum>(E)</enum>
                <text>did not knowingly
				and intentionally alter the transaction history.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HFA6E51A6080F4BE9886A0506418F61A1">
              <enum>(25)</enum>
              <header>Verification
				and verify</header>
              <text>The terms <term>verification</term> and
				<term>verify</term>—</text>
							<subparagraph id="H998EDFF27C1E4ADB8BBE152F6466C237">
                <enum>(A)</enum>
                <text>mean determining
				whether the prescription drug product identifier affixed to, or imprinted upon,
				a package or homogeneous case of the prescription drug product corresponds to
				the standardized numerical identifier or lot number, and expiration date
				assigned to the prescription drug product by the manufacturer or the
				repackager, as applicable; and</text>
							</subparagraph>
              <subparagraph id="HA489DCA56B114FACA6E244F0A8EC620A">
                <enum>(B)</enum>
                <text>include making the
				determination under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:25/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> using human-readable or machine-readable
				methods.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H80286DBE4A984C71B149E176F8B74487">
              <enum>(26)</enum>
              <header>Wholesale
				distributor</header>
              <text display-inline="yes-display-inline">The term
				<term>wholesale distributor</term>—</text>
							<subparagraph id="H3E24863C82104A23BC39EA3684B3E684">
                <enum>(A)</enum>
                <text>means a person
				engaged in wholesale distribution (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>); and</text>
							</subparagraph>
              <subparagraph id="HBB0F7368084F4B7CB5E4D2A9EF3CAA84">
                <enum>(B)</enum>
                <text>excludes—</text>
								<clause id="H92D90374A62A476EBD05C18734F83AF8">
                  <enum>(i)</enum>
                  <text>a
				manufacturer, a co-licensed partner of a manufacturer, or a third-party
				logistics provider, or a dispenser who does not engage in such wholesale
				distribution;</text>
								</clause>
                <clause id="HB00D181173404F02914DB77E682597A1">
                  <enum>(ii)</enum>
                  <text>a
				repackager engaged in such wholesale distribution; or</text>
								</clause>
                <clause id="HA431CEC3884A42E9BF489CDAAE12726E">
                  <enum>(iii)</enum>
                  <text display-inline="yes-display-inline">the distribution of prescription drug
				product or an offer to distribute prescription drug product by an authorized
				repackager that has taken ownership or possession of the prescription drug
				product and repacked the prescription drug product in accordance with the
				requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e" proposed="true">section 582(e)</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
            </paragraph>
          </section>
          <section id="H3EE3EACD2BC24BD19E38596888FD20D4">
            <enum>582.</enum>
            <header>Requirements</header>
						<subsection id="H0320896D1F7B4ED0B774786F209EF851">
              <enum>(a)</enum>
              <header>In
				general</header>
							<paragraph id="H7FAE53EA2A9A41478E0C5F358038104D">
                <enum>(1)</enum>
                <header>Compliance
				required</header>
                <text>An entity that is a manufacturer, repackager, wholesale
				distributor, third-party logistics provider, or dispenser shall comply with the
				requirements of this section. If an entity meets the definition of more than
				one of the entities referred to in the preceding sentence, such entity shall
				comply with all applicable requirements of this section, but shall not be
				required to comply with duplicative requirements.</text>
							</paragraph>
              <paragraph id="H9E371F4267C745B983886DD9B397443E">
                <enum>(2)</enum>
                <header>Standards</header>
                <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, in consultation with
				other appropriate Federal officials, manufacturers, repackagers, wholesale
				distributors, third-party logistics providers, and dispensers, establish, by
				regulation, standards for the exchange of transaction information for purposes
				of complying with this section. The standards established under this paragraph
				shall be in accordance with a form developed by a widely recognized
				international standards development organization. In establishing such
				standards, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consider the feasibility of establishing
				standardized documentation to be used by all members of the pharmaceutical
				distribution supply chain to convey the transaction history and transaction
				statement to the subsequent owner of a prescription drug product. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall publish such standards not later than 180 days after the date of the
				enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">
                    <short-title>Safeguarding America’s
				Pharmaceuticals Act of 2013</short-title>
                  </cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H5AF49A62E18041D6985218AFE8F98114">
                <enum>(3)</enum>
                <header>Waivers,
				exceptions, and exemptions</header>
                <text>Not later than one year after the date
				of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding
				America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				promulgate a regulation to—</text>
								<subparagraph id="HE6FBAE3114294BF8A77671D4202C67B1">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">establish a process by which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				may grant, at the request of an authorized manufacturer, repackager, wholesale
				distributor, or dispenser, a waiver from any of the requirements of this
				section—</text>
									<clause id="HAB1F4B876995401F886BF0936C91E931">
                    <enum>(i)</enum>
                    <text>if
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that such requirements would result in an undue
				economic hardship; or</text>
									</clause>
                  <clause id="H10079706E47F42E5922B842F1E2F1800">
                    <enum>(ii)</enum>
                    <text>for emergency
				medical reasons, including a public health emergency declaration pursuant to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:319">section 319 of the Public Health Service Act</cato:entity-ref>;</text>
									</clause>
                </subparagraph>
                <subparagraph id="H94CFFC66DD324EFF82F376838772B48B">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">establish a process, with respect to the
				prescription drug product identifier requirement under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:2" proposed="true">paragraph (2) of
				subsections (b)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:2" proposed="true">(c)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:2" proposed="true">(d)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:2" proposed="true">(e)</cato:entity-ref> through which—</text>
									<clause id="H24F29BB322F8422BB80AD8985EF72D41">
                    <enum>(i)</enum>
                    <text>a
				manufacturer or repackager may request a waiver with respect to prescription
				drug products that are packaged in a container too small or otherwise unable to
				accommodate a label with sufficient space to bear the information required for
				compliance with such requirement; and</text>
									</clause>
                  <clause id="H15CDB839E7B6428D981E5D11818928A7">
                    <enum>(ii)</enum>
                    <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				determines whether to waive such requirement; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="HD1E935AD7A1542E1A4259DC2252A5E7C">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">establish a process by which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				may add the prescription drug products or transactions that are exempt from the
				requirements of this section.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H4F0444F4406547B1A979ADFB26CC7861">
                <enum>(4)</enum>
                <header>Grandfathered
				persons and prescription drug products</header>
								<subparagraph id="H7C4C4B2131CA409286F22E76C7447C07">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text display-inline="yes-display-inline">Not later than one
				year after the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of
				2013</cato:entity-ref>
                    </short-title>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify, by regulation, whether and
				under what circumstances the prescription drug product identifier requirement
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:2" proposed="true">paragraph (2) of subsections (b)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:2" proposed="true">(c)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:2" proposed="true">(d)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:2" proposed="true">(e)</cato:entity-ref> shall apply to a
				prescription drug product that is in the supply chain on the date of the
				enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s
				Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>.</text>
								</subparagraph>
                <subparagraph commented="no" id="HCE7963C47701454B80AB81F4E5B81748">
                  <enum>(B)</enum>
                  <header>Third-party
				logistics provider licenses</header>
                  <text display-inline="yes-display-inline">Until the date that is 1 year after the
				effective date of the third-party logistics provider licensing requirements
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">section 584</cato:entity-ref>, a third-party logistics provider shall be considered
				<quote>licensed</quote> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:6/sp:B" proposed="true">section 581(6)(B)</cato:entity-ref> unless the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> has made a
				finding that the third-party logistics provider does not utilize good handling
				and distribution practices and publishes notice thereof.</text>
								</subparagraph>
                <subparagraph commented="no" id="H94E2003D5FF1478A84086592CAABB994">
                  <enum>(C)</enum>
                  <header>Label
				changes</header>
                  <text>Changes made to package labels solely to incorporate the
				prescription drug product identifier may be submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in the
				annual report of an establishment, in accordance with section 314.70(d) of
				chapter 21, Code of Federal Regulations (or any successor regulation).</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HEC887035B214406696EBEEC9E0B93970">
              <enum>(b)</enum>
              <header>Manufacturer
				requirements</header>
							<paragraph id="H7A6A98E7F76147F7BBD339828675D217">
                <enum>(1)</enum>
                <header>Prescription
				drug product tracing</header>
								<subparagraph id="H9EF7666E81D74FCBB5F2A785CA58B5ED">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Beginning not later than January 1, 2015, a manufacturer
				shall—</text>
									<clause id="H17325D33C4D94CA5B37FB6ED7A994854">
                    <enum>(i)</enum>
                    <text>prior to, or at
				the time of, each transaction in which such manufacturer transfers ownership of
				a prescription drug product, provide the subsequent owner with the transaction
				history and a transaction statement; and</text>
									</clause>
                  <clause id="HD4454BC3C64E4BB1B58B69B94CFA950A">
                    <enum>(ii)</enum>
                    <text>maintain the
				transaction information for each such transaction for not less than 3 years
				after the date of the transaction.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HB74B5EA32F0D4AB493CAA35F1BEA0F85">
                  <enum>(B)</enum>
                  <header>Requests for
				information</header>
                  <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate
				Federal or State official, in the event of a recall or for the purpose of
				investigating a suspect prescription drug product or an illegitimate
				prescription drug product, a manufacturer shall, not later than 2 business days
				after receiving the request or in such reasonable time as determined by the
				Secretary, provide to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other official, the applicable
				transaction history and transaction statement for the prescription drug
				product.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HB7665169E9C045118490736D8884C8B5">
                <enum>(2)</enum>
                <header>Prescription
				drug product identifier</header>
                <text display-inline="yes-display-inline">Beginning not later than 5 years after the
				date of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding
				America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>, a manufacturer shall affix
				or imprint a prescription drug product identifier on each package and
				homogenous case of a prescription drug product intended to be introduced in a
				transaction. Such manufacturer shall maintain a copy of the prescription drug
				product identifier for such prescription drug product for not less than 3 years
				after the date of the transaction.</text>
							</paragraph>
              <paragraph id="HEB74952643644E518B378C21F11F3D6C">
                <enum>(3)</enum>
                <header>Authorized
				trading partners</header>
                <text>Beginning not later than January 1, 2015, a
				manufacturer shall ensure that each of its trading partners is
				authorized.</text>
							</paragraph>
              <paragraph id="HE04A6EE0FFA14025B5AFE3BC18370C3D">
                <enum>(4)</enum>
                <header>List of
				authorized distributors of record</header>
                <text display-inline="yes-display-inline">Beginning not later than January 1, 2015,
				each manufacturer of a prescription drug shall—</text>
								<subparagraph id="H4D5AD1422C5148789A2930658F87964D">
                  <enum>(A)</enum>
                  <text>maintain a list of
				the authorized distributors of record of such drug at the corporate offices of
				such manufacturer;</text>
								</subparagraph>
                <subparagraph id="H800576C3DBC44BEEB7608D76D588C79C">
                  <enum>(B)</enum>
                  <text>make such list
				publicly available, including placement on the Internet Website of such
				manufacturer; and</text>
								</subparagraph>
                <subparagraph id="H0C2E8D8604FE48219780BF2B19231515">
                  <enum>(C)</enum>
                  <text>update such list
				not less than once per quarter.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H13590CDACC2C4A4486C6EC29E515CD00">
                <enum>(5)</enum>
                <header>Verification</header>
                <text display-inline="yes-display-inline">Beginning not later than January 1, 2015, a
				manufacturer shall implement systems and processes to enable the manufacturer
				to comply with the following requirements:</text>
								<subparagraph id="H5C037AED23004348BDFE8ECF347F8BE9">
                  <enum>(A)</enum>
                  <header>Suspect
				prescription drug product</header>
									<clause id="HB5FB7AB35F2740718E8C05A8F7FB7E7C">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Upon making a determination that a prescription drug
				product in the possession or control of the manufacturer is a suspect
				prescription drug product, or upon receiving a request for verification from
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a prescription drug product within the possession or control
				of a manufacturer is a suspect prescription drug product, a manufacturer shall
				promptly conduct an investigation in coordination with trading partners, as
				applicable, to determine whether the prescription drug product is an
				illegitimate prescription drug product. Beginning not later than 5 years after
				the date of the enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding
				America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                      </short-title>, such investigation shall
				include—</text>
										<subclause id="H6165B296BCA04C60BD3BDDAFC815247B">
                      <enum>(I)</enum>
                      <text>verifying the
				prescription drug product at the package level;</text>
										</subclause>
                    <subclause id="HF3490A1CBBDC48A1A53C32DD87C8237C">
                      <enum>(II)</enum>
                      <text>validating any
				applicable transaction history in the possession of the manufacturer;
				and</text>
										</subclause>
                    <subclause id="H41C5013EDACC414F9CA3E8D7BF44FDC9">
                      <enum>(III)</enum>
                      <text>otherwise
				investigating to determine whether the prescription drug product is an
				illegitimate prescription drug product.</text>
										</subclause>
                  </clause>
                  <clause id="HF9F80318233F4097938E1FAADDCE75B8">
                    <enum>(ii)</enum>
                    <header>Cleared
				prescription drug product</header>
                    <text>If the manufacturer determines that a
				suspect prescription drug product is not an illegitimate prescription drug
				product, the manufacturer shall promptly notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such
				determination and such prescription drug product may be further
				distributed.</text>
									</clause>
                  <clause id="H87CF601189AB4F679DD32DAE68321771">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A
				manufacturer shall keep records of its investigation of a suspect prescription
				drug product for not less than 3 years after the conclusion of the
				investigation.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H67ADADDB65F64ACBAFE453A0DB5195BF">
                  <enum>(B)</enum>
                  <header>Illegitimate
				prescription drug product</header>
									<clause id="HB9EED7BC99C24363A45DD58EDDA98361">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Upon determining that a prescription drug product in the
				possession or control of a manufacturer is an illegitimate prescription drug
				product, the manufacturer shall—</text>
										<subclause id="HF1643F56D5D548B9A8B571A380BADC44">
                      <enum>(I)</enum>
                      <text>quarantine such
				prescription drug product from prescription drug product intended for
				distribution; and</text>
										</subclause>
                    <subclause id="HF2E6AE5FE0EA4661B4DCEDEC8C486F9B">
                      <enum>(II)</enum>
                      <text>provide for the
				disposition of the illegitimate prescription drug product.</text>
										</subclause>
                  </clause>
                  <clause id="HA9D64B2489D44AA288EF19F2C3D35404">
                    <enum>(ii)</enum>
                    <header>Trading
				partner</header>
                    <text display-inline="yes-display-inline">Upon determining that
				a prescription drug product in the possession or control of a trading partner
				is an illegitimate prescription drug product, the manufacturer shall take
				reasonable steps to assist a trading partner to provide for the disposition of
				the illegitimate prescription drug product.</text>
									</clause>
                  <clause id="H89D95204E35F44E28D5311DF0862DB80">
                    <enum>(iii)</enum>
                    <header>Making a
				notification</header>
                    <text>Upon determining that a prescription drug product in
				the possession or control of the manufacturer is an illegitimate prescription
				drug product, the manufacturer shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination
				not later than 24 hours after making such determination. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				determine whether additional trading partner notification is
				appropriate.</text>
									</clause>
                  <clause id="H21AEC84F9D3F45A6A21A56FF87E844A6">
                    <enum>(iv)</enum>
                    <header>Responding to a
				notification</header>
                    <text>Upon the receipt of a notification from the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a determination has been made that a prescription drug product
				is an illegitimate prescription drug product, a manufacturer shall—</text>
										<subclause id="H7E1B5672EBE845E8826FA675675BFCEE">
                      <enum>(I)</enum>
                      <text>identify all
				illegitimate prescription drug products that are subject to such notification
				and in the possession or control of the manufacturer, including any
				prescription drug product that is subsequently received; and</text>
										</subclause>
                    <subclause id="HD1B3D4F5C63C46BC9B9E66B83F3370B3">
                      <enum>(II)</enum>
                      <text>perform the
				activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:b/p:5/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="HBECFC869AD5A455C8CF62B7075891B08">
                    <enum>(v)</enum>
                    <header>Records</header>
                    <text>A
				manufacturer shall keep records of the disposition of an illegitimate
				prescription drug product for not less than 3 years after the conclusion of the
				disposition.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H7AAFAF6EA8AF4130851C3AB23F6DB174">
                  <enum>(C)</enum>
                  <header>Electronic
				database</header>
                  <text>A manufacturer may satisfy the requirements of this
				paragraph through the use of a secure electronic database developed and
				operated by the manufacturer or another entity. The owner of such database
				shall establish the requirements and processes to respond to requests and may
				provide for data access to other members of the pharmaceutical distribution
				supply chain, as appropriate. The development and operation of such a database
				shall not relieve a manufacturer of the requirement under this paragraph to
				respond to a verification request submitted by means other than a secure
				electronic database.</text>
								</subparagraph>
                <subparagraph id="HFC18B91962F449DA975CAA7C63EBB561">
                  <enum>(D)</enum>
                  <header>Returned
				prescription drug product</header>
                  <text>Beginning not later than 5 years after
				the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding
				America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>, upon receipt of a returned
				prescription drug product that the manufacturer intends to further distribute,
				before further distributing such prescription drug product, the manufacturer
				shall—</text>
									<clause id="HE4E5ECC8C62F420D9CD8D0BDF75221D3">
                    <enum>(i)</enum>
                    <text>verify the
				prescription drug product identifier for each sealed homogeneous case of such
				prescription drug product; or</text>
									</clause>
                  <clause id="H2DE67494C67A4BA2A15FF221085A354F">
                    <enum>(ii)</enum>
                    <text>if such
				prescription drug product is not in a sealed homogeneous case, verify the
				prescription drug product identifier on each package.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HAFE1BC24BE8D44A0B53DA1D4B96B9B5D">
              <enum>(c)</enum>
              <header>Wholesale
				distributor requirements</header>
							<paragraph id="H0CD9E13C69544BACBA8989035D9591A3">
                <enum>(1)</enum>
                <header>Prescription
				drug product tracing</header>
								<subparagraph id="HD4ED4FBE79E2424EA0CAB1D8B9514291">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Beginning not later than April 1, 2015, a wholesale
				distributor shall—</text>
									<clause id="HB445112850144AE59E49CB7D4C9913B3">
                    <enum>(i)</enum>
                    <text>not accept
				ownership of a prescription drug product unless the previous owner prior to, or
				at the time of, the transaction provides the applicable transaction history and
				a transaction statement for the prescription drug product;</text>
									</clause>
                  <clause id="H508BCA6E21B74D1A98CD0651E7AF08A2">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">prior to, or at the time of, each
				transaction in which the wholesale distributor transfers ownership of a
				prescription drug product—</text>
										<subclause id="HDDDFDA22A5814097AD58745283F53DA8">
                      <enum>(I)</enum>
                      <text>in the case that
				the wholesale distributor purchased the prescription drug product directly from
				the manufacturer, provide the subsequent owner with transaction history and a
				transaction statement for the prescription drug product; or</text>
										</subclause>
                    <subclause id="H190FF532F8EE4DB49C9925A604C021E9">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">in the case that the wholesale distributor
				did not purchase the prescription drug product directly from the manufacturer,
				the exclusive distributor of the manufacturer, or a repackager that purchased
				directly from the manufacturer, provide the subsequent owner with transaction
				history beginning with the wholesale distributor that did purchase the product
				directly from the manufacturer, the exclusive distributor of the manufacturer,
				or a repackager that purchased directly from the manufacturer;</text>
										</subclause>
                  </clause>
                  <clause id="H02E25F3DA13E4FE381217DD299804217">
                    <enum>(iii)</enum>
                    <text display-inline="yes-display-inline">notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:c/p:1/sp:A/cl:ii" proposed="true">clause (ii)</cato:entity-ref>, if the
				wholesale distributor purchased the prescription drug product directly from the
				manufacturer, its exclusive distributor, or a repackager that purchased
				directly from the manufacturer or its authorized distributor of record—</text>
										<subclause id="HD59464D4405847E9B3AEAD1A04826483">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">provide an initial purchase transaction
				statement on the invoice to the customer, stating that the wholesale
				distributor purchased the prescription drug product package directly from the
				manufacturer, exclusive distributor, or repackager;</text>
										</subclause>
                    <subclause id="H3891A115B5B849149AE750894D2DFB61">
                      <enum>(II)</enum>
                      <text>make available to
				the immediate subsequent recipient of such prescription drug product the
				information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:c/p:1/sp:A/cl:ii" proposed="true">clause (ii)</cato:entity-ref> through any combination of
				self-generated paper, electronic data, or manufacturer provided information on
				the prescription drug product package; and</text>
										</subclause>
                    <subclause id="H2115080D2A754FA8B0969A2C77BB9657">
                      <enum>(III)</enum>
                      <text display-inline="yes-display-inline">for purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:c/p:1/sp:A/cl:iii/scl:I" proposed="true">subclauses (I)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:c/p:1/sp:A/cl:iii/scl:II" proposed="true">(II)</cato:entity-ref>,
				need not include any transactions occurring before the transfer of the
				prescription drug product to the wholesale distributor; and</text>
										</subclause>
                  </clause>
                  <clause id="HA30EB1917879457FA1C0611458250AA1">
                    <enum>(iv)</enum>
                    <text display-inline="yes-display-inline">maintain the transaction information for
				each transaction described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:c/p:1/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:c/p:1/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref> for not less than 3 years
				after the transaction.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="HAA03913555064FA890296AFA5042637D">
                  <enum>(B)</enum>
                  <header>Returns
				exception</header>
									<clause commented="no" id="H2758358340F1469089B582E43E24D7BE">
                    <enum>(i)</enum>
                    <header>Saleable
				returns</header>
                    <text display-inline="yes-display-inline">Notwithstanding
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:c/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, a wholesale distributor may—</text>
										<subclause commented="no" id="H768221642D2B4088B39CB63A0EFACD58">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">accept returned prescription drug product
				without a transaction history from a dispenser; and</text>
										</subclause>
                    <subclause commented="no" id="HFC5675DFB8F941F0A9F135EFFD59E842">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">distribute such returned prescription drug
				product with a transaction history that begins with the wholesale distributor
				that so accepted the returned product.</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="H3DFF9720CB46479E97A8491864DE445A">
                    <enum>(ii)</enum>
                    <header>Nonsaleable
				returns</header>
                    <text>A wholesale distributor may return a nonsaleable
				prescription drug to the manufacturer or repackager, to the wholesale
				distributor from whom such prescription drug was purchased, or to a person
				acting on behalf of such a person, including a returns processor, without
				providing the information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:c/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H16C8DC4A005542A5BB601CDD3AAEE97A">
                  <enum>(C)</enum>
                  <header>Requests for
				information</header>
                  <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate
				Federal or State official, in the event of a recall or for the purpose of
				investigating a suspect prescription drug product or an illegitimate
				prescription drug product a wholesale distributor shall, not later than 2
				business days after receiving the request or in such other reasonable time as
				determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, provide the applicable transaction history and
				transaction statements for the prescription drug product.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H48CD9B2A0CFB452BB7C939121E552488">
                <enum>(2)</enum>
                <header>Prescription
				drug product identifier</header>
                <text>Beginning not later than 7 years after
				the date of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding
				America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>, a wholesale distributor
				may engage in transactions involving a prescription drug product only if such
				prescription drug product is encoded with a prescription drug product
				identifier, except as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:a/p:4" proposed="true">subsection (a)(4)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H4FA5ACC4CAC14190B3D2BCEBA61C4F8F">
                <enum>(3)</enum>
                <header>Authorized
				trading partners</header>
                <text>Beginning not later than January 1, 2015, a
				wholesale distributor shall ensure that each of its trading partners is
				authorized.</text>
							</paragraph>
              <paragraph id="H98B40BC5649A455E94808DE152A94DF2">
                <enum>(4)</enum>
                <header>Verification</header>
                <text>Beginning
				not later than April 1, 2015, a wholesale distributor shall implement systems
				to enable the wholesale distributor to comply with the following
				requirements:</text>
								<subparagraph id="H23A4451869AF4509AF4B37D2FA048B73">
                  <enum>(A)</enum>
                  <header>Suspect
				prescription drug product</header>
									<clause id="H325A5C6D7557427BB898CFCB0A6EDBDA">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Upon making a determination that a prescription drug
				product in the possession or control of the wholesale distributor is a suspect
				prescription drug product, or upon receiving a request for verification from
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a prescription drug product within the possession or control
				of a wholesale distributor is a suspect prescription drug product, a wholesale
				distributor shall promptly conduct an investigation to determine whether the
				prescription drug product is an illegitimate prescription drug product.
				Beginning not later than 7 years after the date of the enactment of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of
				2013</cato:entity-ref>
                      </short-title>, such investigation shall include—</text>
										<subclause id="H6E9225321A45458E99A729306B9FEFC4">
                      <enum>(I)</enum>
                      <text>verifying a
				package of the prescription drug product;</text>
										</subclause>
                    <subclause id="H00BDE0E8F75543A6BEA84EF8C8BC02C3">
                      <enum>(II)</enum>
                      <text>validating any
				applicable transaction history in the possession of the wholesale distributor;
				and</text>
										</subclause>
                    <subclause id="HA49E3B19328D4553A8D9692A65CEB70F">
                      <enum>(III)</enum>
                      <text>otherwise
				investigating to determine whether the prescription drug product is an
				illegitimate prescription drug product.</text>
										</subclause>
                  </clause>
                  <clause id="HDA1BF53757CD4252AC95A5FF2A98E3C0">
                    <enum>(ii)</enum>
                    <header>Cleared
				prescription drug product</header>
                    <text>If the wholesale distributor determines
				that a suspect prescription drug product is not an illegitimate prescription
				drug product, the wholesale distributor shall promptly notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of
				such determination and such prescription drug product may be further
				distributed.</text>
									</clause>
                  <clause id="H670198E37656417D9ED15727B47FC013">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A
				wholesale distributor shall keep records of its investigation of a suspect
				prescription drug product for not less than 3 years after the conclusion of the
				investigation.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H4047F072ADF8456FBE52DF348C2A15E6">
                  <enum>(B)</enum>
                  <header>Illegitimate
				prescription drug product</header>
									<clause id="HC6EDAE148B4F465AAE7B81F7FA7B7490">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Upon receiving notice that a manufacturer of a
				prescription drug product has determined that a prescription drug product in
				the possession or control of a wholesale distributor is an illegitimate
				prescription drug product, the wholesale distributor shall—</text>
										<subclause id="HDD5C6A7D9B4640589E12D999E5999713">
                      <enum>(I)</enum>
                      <text>quarantine such
				prescription drug product within the possession or control of the manufacturer
				from prescription drug product intended for distribution; and</text>
										</subclause>
                    <subclause id="H894BDDD8FC66467687E9AEEB1D2A2CAB">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">provide for the disposition of the
				illegitimate prescription drug product within the possession or control of the
				wholesale distributor.</text>
										</subclause>
                  </clause>
                  <clause id="H182EA27741F74867971E41F4511A4986">
                    <enum>(ii)</enum>
                    <header>Trading
				partner</header>
                    <text display-inline="yes-display-inline">Upon determining that
				a prescription drug product in the possession or control of a trading partner
				is an illegitimate prescription drug product, the wholesale distributor shall
				take reasonable steps to assist a trading partner to provide for the
				disposition of the illegitimate prescription drug product.</text>
									</clause>
                  <clause id="H273C3882DA13481DBBF772D18339B3D3">
                    <enum>(iii)</enum>
                    <header>Making a
				notification</header>
                    <text>Upon determining that a prescription drug product in
				the possession or control of the wholesale distributor is an illegitimate
				prescription drug product, the wholesale distributor shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				of such determination not later than 24 hours after making such determination.
				The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall determine whether additional trading partner notification
				is appropriate.</text>
									</clause>
                  <clause id="HCF7820CA6E774250958F384BD78C1D62">
                    <enum>(iv)</enum>
                    <header>Responding to a
				notification</header>
                    <text>Upon the receipt of a notification from the
				Secretary that a determination has been made that a prescription drug product
				is an illegitimate prescription drug product, a wholesale distributor
				shall—</text>
										<subclause id="HCABBFF528C894F4BAABB9C9010527939">
                      <enum>(I)</enum>
                      <text>identify all
				illegitimate prescription drug product subject to such notification that is in
				the possession or control of the wholesale distributor, including any
				prescription drug product that is subsequently received; and</text>
										</subclause>
                    <subclause id="HBCFDB6C265894822A5E2F5FA3694A386">
                      <enum>(II)</enum>
                      <text>perform the
				activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="H94AF66A157644FA39A021C0774E0F5D0">
                    <enum>(v)</enum>
                    <header>Records</header>
                    <text>A
				wholesale distributor shall keep records of the disposition of an illegitimate
				prescription drug product for not less than 3 years after the conclusion of the
				disposition.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H011D19ECD2D44D569E17831C893D20FB">
                  <enum>(C)</enum>
                  <header>Electronic
				database</header>
                  <text>A wholesale distributor may satisfy the requirements of
				this paragraph through the use of a secure electronic database developed and
				operated by the manufacturer or another entity. The owner of such database
				shall establish the requirements and processes to respond to requests and may
				provide for data access to other members of the pharmaceutical distribution
				supply chain, as appropriate. The development and operation of such a database
				shall not relieve a wholesale distributor of the requirement under this
				paragraph to respond to a verification request submitted by means other than a
				secure electronic database.</text>
								</subparagraph>
                <subparagraph id="HBB0B994B89EF4AD6BC9BD84CA3048E1F">
                  <enum>(D)</enum>
                  <header>Returned
				prescription drug product</header>
                  <text>Beginning not later than 7 years after
				the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding
				America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>, upon receipt of a returned
				prescription drug product that the wholesale distributor intends to further
				distribute, before further distributing such prescription drug product, the
				wholesale distributor shall—</text>
									<clause id="HE3BE656A1F534394B568AEEC730A2A50">
                    <enum>(i)</enum>
                    <text>verify the
				prescription drug product identifier for each sealed homogeneous case of such
				prescription drug product; or</text>
									</clause>
                  <clause id="H2EDDC319EF7042AB84A9F028DCB71D4F">
                    <enum>(ii)</enum>
                    <text>if such
				prescription drug product is not in a sealed homogeneous case, verify the
				prescription drug product identifier on each package.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="H66F76688D21140D9B44A0EEFAB157B46">
              <enum>(d)</enum>
              <header>Dispenser
				requirements</header>
							<paragraph id="H159C995E295E4794B6235924E1EF0363">
                <enum>(1)</enum>
                <header>Prescription
				drug product tracing</header>
								<subparagraph id="HEB7B7110C1A8460195F353FB363CE1C3">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Beginning not later than July 1, 2015, a
				dispenser—</text>
									<clause id="H12B67C138D18491AA4D145E389120DA5">
                    <enum>(i)</enum>
                    <text>shall not accept
				ownership of a prescription drug product, unless the previous owner prior to,
				or at the time of, the transaction, provides transaction history and a
				transaction statement;</text>
									</clause>
                  <clause id="HE515FB2BA8884F17836B11CA824AE5C5">
                    <enum>(ii)</enum>
                    <text>prior to, or at
				the time of, each transaction in which the dispenser transfers ownership of a
				prescription drug product (but not including dispensing to a patient or
				returns) shall provide the subsequent owner with transaction history and a
				transaction statement for the prescription drug product, except that the
				requirements of this clause shall not apply to sales by a dispenser to another
				dispenser to fulfill a specific patient need; and</text>
									</clause>
                  <clause id="H34F2D2CE167045E88C3E5D3A3CBE6DED">
                    <enum>(iii)</enum>
                    <text>shall maintain
				transaction information for a period of not less than 3 years after the date of
				the transaction.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HA85A6A9E38B6485988A46BC799543CCF">
                  <enum>(B)</enum>
                  <header>Agreements with
				third parties</header>
                  <text>A dispenser may enter into a written agreement with
				a third party, including an authorized wholesale distributor, under which the
				third party confidentially maintains the transaction information required to be
				maintained under this subsection on behalf of the dispenser. If a dispenser
				enters into such an agreement, the dispenser shall maintain a copy of the
				written agreement.</text>
								</subparagraph>
                <subparagraph commented="no" id="HFF037B73E4EA478AB4E909BFDFC0BB55">
                  <enum>(C)</enum>
                  <header>Returns
				exception</header>
									<clause commented="no" id="H52984C4E9A224F4EB194E9DA59660E40">
                    <enum>(i)</enum>
                    <header>Saleable
				returns</header>
                    <text display-inline="yes-display-inline">Notwithstanding
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, a dispenser may return prescription drug product to the
				trading partner from which the dispenser obtained the prescription drug product
				without providing the information required under such subparagraph.</text>
									</clause>
                  <clause commented="no" id="H805B25C3637F405D8C8916018D3E5F1B">
                    <enum>(ii)</enum>
                    <header>Nonsaleable
				returns</header>
                    <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, a dispenser may
				return a nonsaleable prescription drug to the manufacturer or repackager, to
				the wholesale distributor from whom such prescription drug was purchased, to a
				returns processor, or to a person acting on behalf of such persons without
				providing the information required under such subparagraph.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HF7AF90D325184FC5B76B9F8F4C017327">
                  <enum>(D)</enum>
                  <header>Requests for
				information</header>
                  <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate
				Federal or State official, in the event of a recall or for the purpose of
				investigating a suspect prescription drug product or an illegitimate
				prescription drug product, a dispenser shall, not later than 2 business days
				after receiving the request or in another such reasonable time as determined by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, provide lot level transaction information.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HD7F4410DE8F84EA9AB263AA551413000">
                <enum>(2)</enum>
                <header>Prescription
				drug product identifier</header>
                <text>Beginning not later than 8 years after
				the date of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding
				America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>, a dispenser may engage in
				transactions involving a prescription drug product only if such prescription
				drug product is encoded with a prescription drug product identifier, except as
				provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:4" proposed="true">subsection (a)(4)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H8582E7AD601E46FC8F31200556AD103F">
                <enum>(3)</enum>
                <header>Authorized
				trading partners</header>
                <text display-inline="yes-display-inline">Beginning
				not later than January 1, 2015, a dispenser shall ensure that each of its
				trading partners is authorized.</text>
							</paragraph>
              <paragraph id="H996B2F1847A44FDEB6939210BFC5576B">
                <enum>(4)</enum>
                <header>Verification</header>
                <text>Beginning
				not later than January 1, 2015, a dispenser shall implement systems to enable
				the dispenser to comply with the following requirements:</text>
								<subparagraph id="HFC673759998F488491B13D7CA4AEA991">
                  <enum>(A)</enum>
                  <header>Suspect
				prescription drug product</header>
									<clause id="H8BFB12B6A22A4CC68DFB41229D5D4A2E">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Upon making a determination that a prescription drug
				product in the possession or control of the dispenser is a suspect prescription
				drug product, or upon receiving a request for verification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				that a prescription drug product within the possession or control of a
				dispenser is a suspect prescription drug product, a dispenser shall promptly
				conduct an investigation to determine whether the prescription drug product is
				an illegitimate prescription drug product. Such investigation shall
				include—</text>
										<subclause id="H6C53919121214E5F9E22B37E2E0BEB15">
                      <enum>(I)</enum>
                      <text>verifying whether
				the lot number of a suspect prescription drug product corresponds with the lot
				number for such prescription drug product;</text>
										</subclause>
                    <subclause id="H59FFBDCEF03B4B5FADD70175D2412461">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">beginning 8 years after the date of the
				enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">
                          <short-title>Safeguarding America’s
				Pharmaceuticals Act of 2013</short-title>
                        </cato:entity-ref>, verifying that the product
				identifier of at least 3 packages or 10 percent of such suspect prescription
				drug product, whichever is greater, or all packages, if there are fewer than 3,
				corresponds with the prescription drug product identifier for such
				product;</text>
										</subclause>
                    <subclause id="HE7F1A3E65D8B41469BBA2BA4BD4654CE">
                      <enum>(III)</enum>
                      <text>validating any
				applicable transaction history in the possession of the dispenser; and</text>
										</subclause>
                    <subclause id="HB32F6978687F4444B71D5A1AE89AB645">
                      <enum>(IV)</enum>
                      <text>otherwise
				investigating to determine whether the prescription drug product is an
				illegitimate prescription drug product.</text>
										</subclause>
                  </clause>
                  <clause id="H9E0FBC60BF8A424285664E7D9E45C4E1">
                    <enum>(ii)</enum>
                    <header>Cleared
				prescription drug product</header>
                    <text>If the dispenser makes the
				determination that a suspect prescription drug product is not an illegitimate
				prescription drug product, the dispenser shall promptly notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of
				such determination and such prescription drug product may be further
				dispensed.</text>
									</clause>
                  <clause id="HDA9AEF9DBCD44C7BAFD2AB80C4E51DBF">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A
				dispenser shall keep records of its investigation of a suspect prescription
				drug product for not less than 3 years after the conclusion of the
				investigation.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HD34F52B5FCD94A82B84D37957099BFB3">
                  <enum>(B)</enum>
                  <header>Illegitimate
				prescription drug product</header>
									<clause id="HB8654413BF754CC19FE80A249BE1C4A8">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text display-inline="yes-display-inline">Upon receiving notice
				that a manufacturer of a prescription drug product has determined that a
				prescription drug product in the possession or control of a dispenser is an
				illegitimate prescription drug product, the dispenser shall—</text>
										<subclause id="H756B74CCE7CE4CE88197882FBD33C113">
                      <enum>(I)</enum>
                      <text>quarantine such
				prescription drug product within the possession or control of the dispenser
				from prescription drug product intended for distribution; and</text>
										</subclause>
                    <subclause id="H66017071679E42289D29D2C1EE1BC6D5">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">provide for the disposition of the
				illegitimate prescription drug product within the possession or control of the
				dispenser.</text>
										</subclause>
                  </clause>
                  <clause id="H8E0F420F3F9E453B87D32A6B2D64B6C8">
                    <enum>(ii)</enum>
                    <header>Trading
				partners</header>
                    <text display-inline="yes-display-inline">Upon determining
				that a prescription drug product in the possession or control of a trading
				partner is an illegitimate prescription drug product, the dispenser shall take
				reasonable steps to assist a trading partner to provide for the disposition of
				the illegitimate prescription drug product.</text>
									</clause>
                  <clause id="HBB6E00EFE5494E17ACB8EB4A3CC05F5F">
                    <enum>(iii)</enum>
                    <header>Making a
				notification</header>
                    <text>Upon determining that a prescription drug product in
				the possession or control of the dispenser is an illegitimate prescription drug
				product, the dispenser shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination not
				later than 24 hours after making such determination. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				determine whether additional trading partner notification is
				appropriate.</text>
									</clause>
                  <clause id="H96A0407928D24FB49743D411F17811C0">
                    <enum>(iv)</enum>
                    <header>Responding to a
				notification</header>
                    <text>Upon the receipt of a notification from the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a determination has been made that a prescription drug product
				is an illegitimate prescription drug product, a dispenser shall—</text>
										<subclause id="H5A4108B23E8A42A88BC7C346D32CAE31">
                      <enum>(I)</enum>
                      <text>identify all
				illegitimate prescription drug products that are subject to such notification
				and in the possession or control of the dispenser, including any prescription
				drug product that is subsequently received; and</text>
										</subclause>
                    <subclause id="HD1067B72A4D843A8BD251D416BE8D09C">
                      <enum>(II)</enum>
                      <text>perform the
				activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="H69D2362F42C7463B97C017EC10170530">
                    <enum>(v)</enum>
                    <header>Records</header>
                    <text>A
				dispenser shall keep records of the disposition of an illegitimate prescription
				drug product for not less than 3 years after the conclusion of the
				disposition.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H5D8A55F2E72B4FE9B20720E957D824CB">
                  <enum>(C)</enum>
                  <header>Electronic
				database</header>
                  <text>A dispenser may satisfy the requirements of this
				paragraph through the use of a secure electronic database developed and
				operated by the manufacturer or another entity. The owner of such database
				shall establish the requirements and processes to enable responding to requests
				and may provide for data access to other members of the pharmaceutical
				distribution supply chain, as appropriate. The development and operation of
				such a database shall not relieve a dispenser of the requirement under this
				paragraph to respond to a verification request submitted by means other than a
				secure electronic database.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HD10041FA908F450694BEBD62FB2D5DDF">
              <enum>(e)</enum>
              <header>Repackager
				requirements</header>
							<paragraph id="HFA8DA002C4FE4338A2D65B1505BB62D4">
                <enum>(1)</enum>
                <header>Prescription
				drug product tracing</header>
								<subparagraph id="H3BDB30CF7F8B4D20A91C618A9CE43A9E">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Beginning not later than January 1, 2015, a repackager
				shall—</text>
									<clause id="H3C6410C3E8D04018A681C7EF6E5118C9">
                    <enum>(i)</enum>
                    <text>not accept
				ownership of a prescription drug product unless the previous owner, prior to,
				or at the time of, the transaction, provides transaction history and a
				transaction statement for the prescription drug product;</text>
									</clause>
                  <clause id="H87600C32304C4A1193D51769F846AD68">
                    <enum>(ii)</enum>
                    <text>prior to, or at
				the time of, each transaction in which the repackager transfers ownership of a
				prescription drug product, provide the subsequent owner with transaction
				history and a transaction statement;</text>
									</clause>
                  <clause id="HC8E5F54025FB4AF395576291959FA74C">
                    <enum>(iii)</enum>
                    <text>maintain the
				transaction information for each transaction described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref>
				for not less than 3 years after the transaction; and</text>
									</clause>
                  <clause id="H1C2C4F8F86D5413AAF14D82D0CBE02E8">
                    <enum>(iv)</enum>
                    <text>maintain records
				that allow the repackager to associate the prescription drug product identifier
				the repackager affixes or imprints with the prescription drug product
				identifier assigned by the original manufacturer of the prescription drug
				product.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H80619CB459714BC6B5BF30BD62357E8E">
                  <enum>(B)</enum>
                  <header>Nonsaleable
				returns</header>
                  <text>A repackager may return a nonsaleable prescription drug
				product to the manufacturer or repackager, to the wholesale distributor from
				whom such prescription drug product was purchased, or to a person acting on
				behalf of such a person, including a returns processor, without providing the
				information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>.</text>
								</subparagraph>
                <subparagraph id="HCE1D4E3836C4443AA62AFDCB2CA35942">
                  <enum>(C)</enum>
                  <header>Requests for
				information</header>
                  <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate
				Federal or State official, in the event of a recall or for the purpose of
				investigating a suspect prescription drug product or an illegitimate
				prescription drug product, a repackager shall, not later than 2 business days
				after receiving the request or in such other reasonable time as determined by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, provide the applicable transaction history and transaction
				statement for the prescription drug product.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HABB45E03664B4B2A856B95FEE46AD20D">
                <enum>(2)</enum>
                <header>Prescription
				drug product identifier</header>
                <text>Beginning not later than 6 years after
				the date of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding
				America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>, a repackager—</text>
								<subparagraph id="H3E79C0EB33B6473186690119D91B6F69">
                  <enum>(A)</enum>
                  <text>shall affix or
				imprint a prescription drug product identifier to each package and homogenous
				case of prescription drug product intended to be introduced in a
				transaction;</text>
								</subparagraph>
                <subparagraph id="H834231B5D72046FBB922EAE16FA91308">
                  <enum>(B)</enum>
                  <text>shall maintain the
				prescription drug product identifier for such prescription drug product for not
				less than 3 years after the date of the transaction; and</text>
								</subparagraph>
                <subparagraph id="H95748FF98A0745D6B504A9624130DEEB">
                  <enum>(C)</enum>
                  <text>may engage in
				transactions involving a prescription drug product only if such prescription
				drug product is encoded with a prescription drug product identifier except as
				provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:4" proposed="true">subsection (a)(4)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H24F309B780344E22AB723FF23E5974D5">
                <enum>(3)</enum>
                <header>Authorized
				trading partners</header>
                <text display-inline="yes-display-inline">Beginning on
				January 1, 2015, a repackager shall ensure that each of its trading partners is
				authorized.</text>
							</paragraph>
              <paragraph id="HA7D0EA12FDFB4637AD46D91F4AC2CF1B">
                <enum>(4)</enum>
                <header>Verification</header>
                <text>Beginning
				not later than January 1, 2015, a repackager shall implement systems to enable
				the repackager to comply with the following requirements:</text>
								<subparagraph id="H3A62C67C148545F5A2C55F76B043C007">
                  <enum>(A)</enum>
                  <header>Suspect
				prescription drug product</header>
									<clause id="HE0B4F2FE63344CC8AD0B02BE93C3F961">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Upon making a determination that a prescription drug
				product in the possession or control of the repackager is a suspect
				prescription drug product, or upon receiving a request for verification from
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a prescription drug product within the possession or control
				of a repackager is a suspect prescription drug product, a repackager shall
				promptly conduct an investigation to determine whether the prescription drug
				product is an illegitimate prescription drug product, including—</text>
										<subclause id="H2BE1C26C444A4A88983CFD61616043AC">
                      <enum>(I)</enum>
                      <text>beginning not
				later than 6 years after the date of the enactment of the
				<short-title>
                          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of
				2013</cato:entity-ref>
                        </short-title>, verifying the prescription drug product at the package
				level;</text>
										</subclause>
                    <subclause id="HD43B7B13AD904878882E93509AD78D3F">
                      <enum>(II)</enum>
                      <text>validating any
				applicable transaction information in the possession of the repackager;
				and</text>
										</subclause>
                    <subclause id="HD86FF7CC01884954AA6528938C90D8CB">
                      <enum>(III)</enum>
                      <text>otherwise
				investigating to determine whether the prescription drug product is an
				illegitimate prescription drug product.</text>
										</subclause>
                  </clause>
                  <clause id="H3B65D69F5117449586ED07CD9C6222C3">
                    <enum>(ii)</enum>
                    <header>Cleared
				prescription drug product</header>
                    <text>If the repackager determines that a
				suspect prescription drug product is not an illegitimate prescription drug
				product, the repackager shall promptly notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such
				determination and such prescription drug product may be further
				distributed.</text>
									</clause>
                  <clause id="H0723A658EC6D440AB2221496570140B3">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A
				repackager shall keep records of its investigation of a suspect prescription
				drug product for not less than 3 years after the conclusion of the
				investigation.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HE0BB824F2A2F41CE819812D5FEA944F8">
                  <enum>(B)</enum>
                  <header>Illegitimate
				prescription drug product</header>
									<clause id="HBCB21F299B684FDE89C769E79D5135BC">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text display-inline="yes-display-inline">Upon receiving notice
				that a manufacturer of a prescription drug product has determined that a
				prescription drug product in the possession or control of a repackager is an
				illegitimate prescription drug product, the repackager shall—</text>
										<subclause id="H998A9C70946A46728C806136F3D049EE">
                      <enum>(I)</enum>
                      <text>quarantine such
				prescription drug product within the possession or control of the repackager
				from prescription drug product intended for distribution; and</text>
										</subclause>
                    <subclause id="HA09ECBBB2B4745838A72B3956F429FEF">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">provide for the disposition of the
				illegitimate prescription drug product within the possession or control of the
				repackager.</text>
										</subclause>
                  </clause>
                  <clause id="HFB0E777C36834934BD076C39462CE2C1">
                    <enum>(ii)</enum>
                    <header>Trading
				partner</header>
                    <text display-inline="yes-display-inline">Upon determining that
				a prescription drug product in the possession or control of a trading partner
				is an illegitimate prescription drug product, the repackagers shall take
				reasonable steps to assist the trading partner to provide for the disposition
				of the illegitimate prescription drug product.</text>
									</clause>
                  <clause id="H1EE2DF7A82E049DBAAB912B97FEDA1AF">
                    <enum>(iii)</enum>
                    <header>Making a
				notification</header>
                    <text>Upon determining that a prescription drug product in
				the possession or control of the repackager is an illegitimate prescription
				drug product, the repackager shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination
				not later than 24 hours after making such determination. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				determine whether additional trading partner notification is
				appropriate.</text>
									</clause>
                  <clause id="H2F9A7E87A5F24CECA7FB1084DB0E0AD5">
                    <enum>(iv)</enum>
                    <header>Responding to a
				notification</header>
                    <text>Upon the receipt of a notification from the
				Secretary that a determination has been made that a prescription drug product
				is an illegitimate prescription drug product, a repackager shall—</text>
										<subclause id="H1656C126FAA84729BBBDF4F7A26DB9F7">
                      <enum>(I)</enum>
                      <text>identify all
				illegitimate prescription drug products that are subject to such notification
				and in the possession or control of the repackager, including any prescription
				drug product that is subsequently received; and</text>
										</subclause>
                    <subclause id="H074710A06A53481C9F3E3FE20E488F87">
                      <enum>(II)</enum>
                      <text>perform the
				activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                  <clause id="H28038656289B4BAEBD4114CCDDB729DB">
                    <enum>(v)</enum>
                    <header>Records</header>
                    <text>A
				repackager shall keep records of the disposition of an illegitimate
				prescription drug product for not less than 3 years after the conclusion of the
				disposition.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H4B31006B5D7F421EBBBF74D0479752A9">
                  <enum>(C)</enum>
                  <header>Electronic
				database</header>
                  <text>A repackager may satisfy the requirements of this
				paragraph through the use of a secure electronic database developed and
				operated by the manufacturer or another entity. The owner of such database
				shall establish the requirements and processes to respond to requests and may
				provide for data access to other members of the pharmaceutical distribution
				supply chain, as appropriate. The development and operation of such a database
				shall not relieve a repackager of the requirement under this paragraph to
				respond to a verification request submitted by means other than a secure
				electronic database.</text>
								</subparagraph>
                <subparagraph id="H3FF079B2D77C4531A447CF56246CA0DE">
                  <enum>(D)</enum>
                  <header>Returned
				prescription drug product</header>
                  <text>Beginning not later than 6 years after
				the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding
				America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>, upon receipt of a returned
				prescription drug product that the repackager intends to further distribute,
				before further distributing such prescription drug product, the repackager
				shall—</text>
									<clause id="H78000A8404904D648BD1CB33CC705294">
                    <enum>(i)</enum>
                    <text>verify the
				prescription drug product identifier for each sealed homogeneous case of such
				prescription drug product; or</text>
									</clause>
                  <clause id="H9F872917A53A421882E61921D7E7211F">
                    <enum>(ii)</enum>
                    <text>if such
				prescription drug product is not in a sealed homogeneous case, verify the
				prescription drug product identifier on each package.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HCE20624B5070489FAA31FECA26F5D04D">
              <enum>(f)</enum>
              <header>Third-Party
				logistics provider requirements</header>
							<paragraph id="HA47DD9FA292E42EDA3BB45011B3384F2">
                <enum>(1)</enum>
                <header>Authorized
				trading partners</header>
                <text display-inline="yes-display-inline">Beginning on
				January 1, 2015, a third-party logistics provider shall ensure that each of its
				trading partners is authorized.</text>
							</paragraph>
              <paragraph id="HD7643DEDB8494CCA932F866E4D31BCD6">
                <enum>(2)</enum>
                <header>Verification</header>
                <text display-inline="yes-display-inline">Beginning not later than January 1, 2015, a
				third-party logistics provider shall implement systems to enable the
				third-party logistics provider to comply with the following
				requirements:</text>
								<subparagraph id="HE8E03FA025B746B9A6C93EC8F5740566">
                  <enum>(A)</enum>
                  <header>Suspect
				prescription drug product</header>
									<clause id="H1D773CFDC543400E9E2E929110800D3E">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Upon making a determination that a prescription drug
				product in the possession or control of a third-party logistics provider is a
				suspect prescription drug product, a third-party logistics provider shall
				promptly notify the owner of such prescription drug product of the need to
				conduct an investigation to determine whether the prescription drug product is
				an illegitimate prescription drug product.</text>
									</clause>
                  <clause id="HF94C4456F89249D58AE19643115ACBBC">
                    <enum>(ii)</enum>
                    <header>Cleared
				prescription drug product</header>
                    <text>If the owner of the prescription drug
				product notifies the third-party logistics provider of the determination that a
				suspect prescription drug product is not an illegitimate prescription drug
				product, such prescription drug product may be further distributed.</text>
									</clause>
                  <clause id="H71A070EC7410438298F95CBE6E4FA97E">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A
				third-party logistics provider shall keep records of the activities described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref> with respect to a suspect prescription drug product for
				not less than 3 years after the conclusion of the investigation.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HB5CD8BF9400D4FDF8BD55CA115A0D6F8">
                  <enum>(B)</enum>
                  <header>Illegitimate
				prescription drug product</header>
									<clause id="HA9572BA2EF1F47C2AD5C82B39216CF73">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text display-inline="yes-display-inline">Upon receiving notice
				that a manufacturer of a prescription drug product has determined that a
				prescription drug product in the possession or control of a third-party
				logistics provider is an illegitimate prescription drug product, the
				third-party logistics provider shall—</text>
										<subclause id="H3B212DEA88AC4BFEAF6F5D78357C18BE">
                      <enum>(I)</enum>
                      <text>quarantine such
				prescription drug product within the possession or control of the third-party
				logistics provider from prescription drug product intended for
				distribution;</text>
										</subclause>
                    <subclause id="HF4EE84141F354C95823E7ABF95A51DA3">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">promptly notify the owner of such
				prescription drug product of the need to provide for the disposition of such
				prescription drug product; and</text>
										</subclause>
                    <subclause id="H3E99016E735341F8A6D2A88C54815273">
                      <enum>(III)</enum>
                      <text display-inline="yes-display-inline">promptly transfer possession of the
				prescription drug product to the owner of such prescription drug product to
				provide for the disposition of the prescription drug product.</text>
										</subclause>
                  </clause>
                  <clause id="HD44085E19F7744E9A9D86EB05DC4791A">
                    <enum>(ii)</enum>
                    <header>Making a
				notification</header>
                    <text>Upon determining that a prescription drug product in
				the possession or control of the third-party logistics provider is an
				illegitimate prescription drug product, the third-party logistics provider
				shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than 24 hours after making such
				determination. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall determine whether additional trading partner
				notification is appropriate.</text>
									</clause>
                  <clause id="H99370FE23CC948C290B1B1F4469BEE7D">
                    <enum>(iii)</enum>
                    <header>Responding to
				a notification</header>
                    <text>Upon the receipt of a notification from the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, a third-party logistics provider shall—</text>
										<subclause id="H3A8A2DF3697B4DB69F41DAAFB6CDC604">
                      <enum>(I)</enum>
                      <text>identify all
				illegitimate prescription drug product subject to such notification that is in
				the possession or control of the third-party logistics provider, including any
				prescription drug product that is subsequently received; and</text>
										</subclause>
                    <subclause id="H6FCD43C3849743589090EE9C96749C69">
                      <enum>(II)</enum>
                      <text>perform the
				activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                  <clause id="H04068EB593CB44A2995143B7294799AA">
                    <enum>(iv)</enum>
                    <header>Records</header>
                    <text>A
				third-party logistics provider shall keep records of the activities described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref> with respect to an illegitimate prescription drug
				product for not less than 3 years after the conclusion of the
				disposition.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HD0939BD9779E443BAADEF9DB9722A5F4">
              <enum>(g)</enum>
              <header>Drop
				shipments</header>
              <text>This section does not apply to any entity,
				notwithstanding its status as a wholesale distributor or repackager, or other
				status that is not involved in the physical handling, distribution, or storage
				of a prescription drug product. For purposes of this subsection, facilitating
				the distribution of a prescription drug product by providing various
				administrative services, including processing of orders and payments, shall
				not, by itself, be construed as being involved in the handling, distribution,
				or storage of a prescription drug
				product.</text>
						</subsection>
          </section>
        </subchapter>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H801E4EA5B0CE4E55A5615C152565C568">
      <enum>3.</enum>
      <header>Enhanced drug
			 distribution security</header>
			<subsection id="HD75E28EF70E04D62A4621FB7D78B992F">
        <enum>(a)</enum>
        <header>Pilot
			 projects</header>
				<paragraph id="HA9A4BF9AAE004F0BA5E8ACBE101C613A">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text>Not later than 2 years after the date of the enactment of
			 this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish one or more pilot projects in
			 coordination with manufacturers, repackagers, wholesale distributors,
			 third-party logistics providers, and dispensers to explore and evaluate methods
			 to enhance the safety and security of the pharmaceutical distribution supply
			 chain.</text>
				</paragraph>
        <paragraph id="HDC0B2C3AE9B5416B846C8668F4DA7526">
          <enum>(2)</enum>
          <header>Content</header>
					<subparagraph id="HEC84A693B8BA43F0A25A3DF4164A15B1">
            <enum>(A)</enum>
            <header>In
			 general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall ensure that the pilot projects under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref> collectively—</text>
						<clause id="H960ACB075531462CA4EA3DB8EEFBB391">
              <enum>(i)</enum>
              <text>reflect the
			 diversity of the pharmaceutical distribution supply chain; and</text>
						</clause>
            <clause id="HBA605D589CA04C559C3625E0F52916BB">
              <enum>(ii)</enum>
              <text>include
			 participants representative of every sector within the pharmaceutical
			 distribution supply chain, including participants representative of small
			 businesses.</text>
						</clause>
          </subparagraph>
          <subparagraph id="H9DFA5A06C92247BC9B1D713E583F890D">
            <enum>(B)</enum>
            <header>Project
			 design</header>
            <text>The pilot projects shall be designed to—</text>
						<clause id="H9F184BF1C91A4ED695F0FDC51FFF308D">
              <enum>(i)</enum>
              <text>utilize the
			 prescription drug product identifier for tracing of a prescription drug
			 product, which utilization may include—</text>
							<subclause id="H341769556AF740B58D73DF9702D13578">
                <enum>(I)</enum>
                <text>verification of
			 the prescription drug product identifier of a prescription drug product;
			 and</text>
							</subclause>
              <subclause id="HD629D35C311A48118CA5DE4FC3E0F54D">
                <enum>(II)</enum>
                <text>the use of
			 aggregation and inference;</text>
							</subclause>
            </clause>
            <clause id="H5E0145859D48420BBA5906BEF4E0A3D0">
              <enum>(ii)</enum>
              <text>improve the
			 technical capabilities of each sector within the pharmaceutical supply chain to
			 comply with systems and processes needed to utilize the prescription drug
			 product identifiers to enhance tracing of a prescription drug product;
			 and</text>
						</clause>
            <clause id="H7F0880D5A3F74DFAB0060E7616F5D05D">
              <enum>(iii)</enum>
              <text>conduct such
			 other activities as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines appropriate to explore and
			 evaluate methods to enhance the safety and security of the pharmaceutical
			 distribution supply chain.</text>
						</clause>
          </subparagraph>
        </paragraph>
      </subsection>
      <subsection id="HD21507B80F0D48F8BC15C7CEEEA7375D">
        <enum>(b)</enum>
        <header>Public
			 meetings</header>
				<paragraph id="H7C57DACF352F4E4BAEF052DDD3BAB0C1">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text>Not later than 6 months after the date of the enactment
			 of this Act, and at least every 6 months thereafter until the submission of the
			 report required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:2" proposed="true">subsection (d)(2)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall hold a public meeting
			 to enhance the safety and security of the pharmaceutical distribution supply
			 chain. In conducting such meetings, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall take all measures
			 reasonable and practicable to ensure the protection of confidential commercial
			 information and trade secrets.</text>
				</paragraph>
        <paragraph id="H224A104F95B34A7BAAB95B957F4A4A59">
          <enum>(2)</enum>
          <header>Content</header>
          <text>In
			 conducting meetings under this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall seek to address,
			 in at least one such meeting, each of the following topics:</text>
					<subparagraph id="HFA76756BE9A746D58A72376691B92203">
            <enum>(A)</enum>
            <text>Best practices in
			 each of the sectors within the pharmaceutical distribution supply chain to
			 implement the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>.</text>
					</subparagraph>
          <subparagraph id="H8AE4BFBFB2254E729D7B14B3AF1FBDC6">
            <enum>(B)</enum>
            <text>The costs and
			 benefits of implementation of such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref>, including the impact on each
			 pharmaceutical distribution supply chain sector and on public health.</text>
					</subparagraph>
          <subparagraph commented="no" id="H9DF50C40A8CD4E36B263ACCF108D4668">
            <enum>(C)</enum>
            <text>Whether additional
			 electronic traceability requirements, including tracing of prescription drug
			 product at the package level, are feasible, cost effective, overly burdensome
			 on small businesses, and needed to protect public health.</text>
					</subparagraph>
          <subparagraph id="HE193B0D67AAC402F965454AF83040772">
            <enum>(D)</enum>
            <text>The systems and
			 processes needed to utilize the prescription drug product identifiers to
			 enhance tracing of prescription drug product at the package level.</text>
					</subparagraph>
          <subparagraph id="HF6EDCED061B9461C9782C13BD38EC280">
            <enum>(E)</enum>
            <text>The technical
			 capabilities and legal authorities, if any, needed to establish an electronic
			 system that provides for enhanced tracing of prescription drug product at the
			 package level.</text>
					</subparagraph>
          <subparagraph id="HCE081DB2DC6A418A949A0EFA99480B87">
            <enum>(F)</enum>
            <text>The impact that
			 the requirements, systems, processes, capabilities, and legal authorities
			 referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b/p:2/sp:C" proposed="true">subparagraphs (C)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b/p:2/sp:D" proposed="true">(D)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b/p:2/sp:E" proposed="true">(E)</cato:entity-ref> would have on patient safety,
			 the drug supply, cost and regulatory burden, the timeliness of patient access
			 to prescription drugs, and small businesses.</text>
					</subparagraph>
        </paragraph>
      </subsection>
      <subsection id="H6B10C463A8C140DD9A68A29F43F29A88">
        <enum>(c)</enum>
        <header>Study of the
			 pharmaceutical distribution supply chain</header>
				<paragraph id="H8F0532DBB2214457B2AC238D23D1FC39">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller
			 General of the United States</cato:entity-ref> shall conduct a study to examine implementation of
			 the requirements established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">subchapter H of chapter V of the Federal
			 Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>, in order to inform the
			 regulations promulgated under this section.</text>
				</paragraph>
        <paragraph id="HA86723FD0A484F7E811400521E0C1A0C">
          <enum>(2)</enum>
          <header>Consideration</header>
          <text>In
			 conducting the study under this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General</cato:entity-ref> shall
			 provide for stakeholder input and shall consider the following:</text>
					<subparagraph id="H4873F00ADC9A4892B8CEA2037C7017C3">
            <enum>(A)</enum>
            <text>The implementation
			 of the requirements established under such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">subchapter H</cato:entity-ref> with respect to—</text>
						<clause id="HA5C3CCC491B74F84AC8C4010CB30DA1A">
              <enum>(i)</enum>
              <text>the
			 ability of the health care system collectively to maintain patient access to
			 medicines;</text>
						</clause>
            <clause id="H2B1189BD4E5247C49AF39498030158CF">
              <enum>(ii)</enum>
              <text>the
			 scalability of such requirements, including with respect to prescription drug
			 product lines; and</text>
						</clause>
            <clause id="H4D45011AF55F499492F2D0C510C7125C">
              <enum>(iii)</enum>
              <text>the capability
			 of different sectors within the pharmaceutical distribution supply chain,
			 including small businesses, to affix and utilize the prescription drug product
			 identifier.</text>
						</clause>
          </subparagraph>
          <subparagraph id="HC41A7D8F8F77420DA03FA3AD71880C13">
            <enum>(B)</enum>
            <text>The need for
			 additional legal authorities and activities to address additional gaps in the
			 pharmaceutical distribution supply chain, if any, after the implementation of
			 the requirements established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">such subchapter H</cato:entity-ref> with respect to—</text>
						<clause id="HF1A04AB315A74E07923F6A51AB136625">
              <enum>(i)</enum>
              <text>the
			 systems and processes needed to enhance tracing of prescription drug product at
			 the package level;</text>
						</clause>
            <clause id="H8D20D4FFBEF045BE95702A90202A9881">
              <enum>(ii)</enum>
              <text>the
			 impact, feasibility, and cost effectiveness that additional requirements
			 pursuant to this section would have on each pharmaceutical distribution supply
			 chain sector and the public health; and</text>
						</clause>
            <clause id="H78BF33860B03425F9C0182A20F90D45C">
              <enum>(iii)</enum>
              <text>the systems and
			 processes needed to enhance interoperability among trading partners.</text>
						</clause>
          </subparagraph>
          <subparagraph id="HB2C4E02A29F0499F97A78B7098E27EC3">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">Risks to the security and privacy of data
			 collected, maintained, or exchanged pursuant to the requirements established
			 under such subchapter H.</text>
					</subparagraph>
        </paragraph>
      </subsection>
      <subsection id="H520F6E5342E94AB4AB278AFB41356DAC">
        <enum>(d)</enum>
        <header>Small
			 dispensers</header>
				<paragraph id="H5B20509662234E5DA9DDB332BAD47113">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text display-inline="yes-display-inline">Not later than 10
			 years after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall enter
			 into a contract with a private, independent consulting firm with relevant
			 expertise to conduct a technology and software study on the feasibility of
			 dispensers that have 25 or fewer full-time employees conducting interoperable,
			 electronic tracing of prescription drug products at the package level.</text>
				</paragraph>
        <paragraph id="H69B504B7BD2F4F99B3C9367A9BF9F78E">
          <enum>(2)</enum>
          <header>Condition</header>
          <text display-inline="yes-display-inline">As a condition of the award of a contract
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref>, the private independent consulting firm awarded such
			 contract shall agree to consult with dispensers that have 25 or fewer full-time
			 employees when conducting the study under such subparagraph.</text>
				</paragraph>
        <paragraph id="HF91373C6096642AFBFCC3A7838A7189A">
          <enum>(3)</enum>
          <header>Study
			 content</header>
          <text>The study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall assess
			 whether, with respect to conducting interoperable, electronic tracing of
			 prescription drug products at the package level, the necessary hardware and
			 software—</text>
					<subparagraph id="HC4CA7A5194BF45E9998FA06704B442E1">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">is readily accessible to such
			 dispensers;</text>
					</subparagraph>
          <subparagraph id="H8DEC597A749D4B83BB3AC7679C5289E6">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">is not prohibitively expensive to obtain,
			 install and maintain for such dispensers; and</text>
					</subparagraph>
          <subparagraph id="H77D31482E1A7401C99472EFB96943C66">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">can be integrated into business practices,
			 such as interoperability with wholesale distributors, for such
			 dispensers.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H5C3ACE94376A422EB381F5BB1CC06837">
          <enum>(4)</enum>
          <header>Publication</header>
          <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish—</text>
					<subparagraph id="H612D69262BFB4965B728288E8934020C">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">the statement of work for the study
			 conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> for public comment not later than 30 days before
			 commencing the study; and</text>
					</subparagraph>
          <subparagraph id="HEF14E05E889E4E4E8C6B6F9876B667F4">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">the final version of such study for public
			 comment not later than 30 days after such study is completed.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H855A05A66CC34D0EAB8BF5E2D7919019">
          <enum>(5)</enum>
          <header>Report to
			 Congress</header>
          <text display-inline="yes-display-inline">Not later than 30
			 days after the date on which the study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> is
			 completed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce
			 of the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor,
			 and Pensions of the Senate</cato:entity-ref>, a report on the findings of the study and any
			 recommendations to improve the technology and software available to small
			 dispensers for purposes of conducting electronic, interoperable tracing of
			 prescription drug products at the package level.</text>
				</paragraph>
        <paragraph id="H3F5FDCBE34714AEFAE206FF34A9E99EF">
          <enum>(6)</enum>
          <header>Public
			 meeting</header>
          <text display-inline="yes-display-inline">Not later than 180
			 days after the date on which the study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> is
			 completed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall hold a public meeting at which members of the
			 public, including stakeholders, may present their views on the study.</text>
				</paragraph>
      </subsection>
      <subsection id="H7195EEB8E0614A4FB4C4FA82F274379C">
        <enum>(e)</enum>
        <header>Reports</header>
				<paragraph id="HB449A1E03CFA4397AC83D984AA181076">
          <enum>(1)</enum>
          <header>GAO
			 report</header>
          <text>Not later than 12 years after the date of the enactment of
			 this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and
			 Commerce of the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health,
			 Education, Labor, and Pensions of the Senate</cato:entity-ref> a report on the results of the
			 study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="H860A1794602C42D194863156ED2BB622">
          <enum>(2)</enum>
          <header>FDA
			 report</header>
          <text>Not later than 12 years after the date of the enactment of
			 this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of
			 the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor, and
			 Pensions of the Senate</cato:entity-ref> a report on the results of the pilot program conducted
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:a" proposed="true">subsection (a)</cato:entity-ref>, taking into consideration—</text>
					<subparagraph id="HECBE6AEAD3EE4ED7B7A794323BD17441">
            <enum>(A)</enum>
            <text>the comments
			 received during the public meetings conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b" proposed="true">subsection (b)</cato:entity-ref>; and</text>
					</subparagraph>
          <subparagraph id="HE030A59341F04EFD99DCA181C1CDFD4E">
            <enum>(B)</enum>
            <text>the results of the
			 study conducted, and the public comments received during the public meeting
			 held, under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d" proposed="true">subsection (d)</cato:entity-ref>.</text>
					</subparagraph>
        </paragraph>
      </subsection>
      <subsection id="H6F65BEEF228044EC8C80B8C4E8083E3B">
        <enum>(f)</enum>
        <header>Establishment of
			 additional requirements</header>
				<paragraph id="HF29FA2EC66DE476BAE5BFF9EA306E645">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text display-inline="yes-display-inline">Notwithstanding any
			 other provision of this Act, including the amendments made by this Act, not
			 earlier than January 1, 2027, and not later than March 1, 2027, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
			 shall issue proposed regulations that establish additional requirements to
			 prevent a suspect product, illegitimate product, or a product that is
			 counterfeit, stolen, diverted, or otherwise unfit for distribution from
			 entering into or being further distributed in the supply chain,
			 including—</text>
					<subparagraph id="H89A00B2093DF4932BC245EA6644BCA2A">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">requirements related to the use of
			 interoperable electronic systems and technologies for enhanced tracing of
			 prescription drug product at the package level, which may include verification
			 of the prescription drug product identifier of a package of prescription drug
			 product and enhanced verification of saleable returns;</text>
					</subparagraph>
          <subparagraph id="HE5841EC6F90B4B04A935DFE8A34B17E9">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">requirements related to the use of
			 additional prescription drug product identifiers or prescription drug product
			 identifier technology that meet the standards developed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:2" proposed="true">section 582(a)(2)
			 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>;</text>
					</subparagraph>
          <subparagraph id="H06FA84BD19A040A884E9CA6BC2FB2519">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">requirements related to the use of
			 aggregation, inference, and other methods, if determined to be necessary
			 components of the systems and technologies referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>;
			 and</text>
					</subparagraph>
          <subparagraph id="HC4FA00A8603544D9B9634108ECDFED07">
            <enum>(D)</enum>
            <text>other data
			 transmission and maintenance requirements and interoperability
			 standards.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H78FFBB39EBDA43CD9EF6C72EA286CBD2">
          <enum>(2)</enum>
          <header>Flexibility</header>
          <text>The
			 requirements described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall provide for flexibility for a
			 member of the pharmaceutical supply chain, by—</text>
					<subparagraph id="H61AB28276F1541ACA0AF5470F452BEE0">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">with respect to dispensers, allowing a
			 dispenser to enter into a written agreement with a third party, including an
			 authorized wholesale distributor, under which—</text>
						<clause id="HBB6E285C640E49D3BDD5B7ECD57BB5EF">
              <enum>(i)</enum>
              <text>the
			 third party confidentially maintains any information required to be maintained
			 under such requirements for the dispenser; and</text>
						</clause>
            <clause id="HC82F6EF1418149F996CFB98A14923481">
              <enum>(ii)</enum>
              <text>the
			 dispenser maintains a copy of the written agreement and is not relieved of the
			 other obligations of the dispenser under such requirements;</text>
						</clause>
          </subparagraph>
          <subparagraph id="H427C0CD9A4924BEF9262A5173AF40A54">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">establishing a process by which an
			 authorized manufacturer, repackager, wholesale distributor, or dispenser may
			 request a waiver from any such requirements if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that
			 such requirements would result in an undue economic hardship on the
			 manufacturer, wholesale distributor, or dispenser;</text>
					</subparagraph>
          <subparagraph id="HCC644E00F5AE4BC49C36DF6014ED2E8B">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">not requiring the adoption of specific
			 business systems by a member of the pharmaceutical supply chain for the
			 maintenance and transmission of prescription drug product tracing data;
			 and</text>
					</subparagraph>
          <subparagraph id="H14B6AC884F4C425782884FEF25942DF3">
            <enum>(D)</enum>
            <text display-inline="yes-display-inline">prescribing alternative methods of
			 compliance for small businesses, as specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:4" proposed="true">paragraph (4)</cato:entity-ref>.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="HBE1999FCD9EA42EB9BDCCFEDB56AD4BC">
          <enum>(3)</enum>
          <header>Considerations</header>
          <text>In
			 issuing proposed regulations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
			 consider—</text>
					<subparagraph id="H91FA671D32D74DF38DF84586E21E68C0">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">the results of the pilot project conducted
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:a" proposed="true">subsection (a)</cato:entity-ref>;</text>
					</subparagraph>
          <subparagraph id="HCB6988A293B94D4CAB110D9809710BD8">
            <enum>(B)</enum>
            <text>the public
			 meetings held under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b" proposed="true">subsection (b)</cato:entity-ref>;</text>
					</subparagraph>
          <subparagraph id="HF8C87AC5B0BA494883B87D504995F5B2">
            <enum>(C)</enum>
            <text>the studies
			 conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:c" proposed="true">subsections (c)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d" proposed="true">(d)</cato:entity-ref>;</text>
					</subparagraph>
          <subparagraph id="H70E9DACB597F43A78D488D4D17BD5199">
            <enum>(D)</enum>
            <text>the reports
			 submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:e" proposed="true">subsection (e)</cato:entity-ref>;</text>
					</subparagraph>
          <subparagraph id="H1484B04E98AE4E55BB435B040BE5F9C2">
            <enum>(E)</enum>
            <text display-inline="yes-display-inline">the public health benefits of such
			 regulations compared with the cost of compliance with the requirements
			 contained in such regulations, including with respect to entities of varying
			 sizes and capabilities; and</text>
					</subparagraph>
          <subparagraph id="HD7E621448745449DA40E7ED0F9D728F9">
            <enum>(F)</enum>
            <text display-inline="yes-display-inline">the diversity of the pharmaceutical
			 distribution supply chain by providing appropriate flexibility for each sector
			 in the supply chain, including small businesses.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="HDD32DB0F1E694C8CBA17521413F4489C">
          <enum>(4)</enum>
          <header>Small business
			 protection</header>
          <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>,
			 taking into consideration the study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d" proposed="true">paragraph (d)</cato:entity-ref>, shall, if
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that the requirements established pursuant to
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref> would result in an undue economic hardship on small businesses,
			 provide for alternative methods of compliance with any such requirement by
			 small businesses, including—</text>
					<subparagraph id="HDF60726DBAA443A79B9F5E7E433B96FD">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">establishing timelines for such compliance
			 (including compliance by dispensers with 25 or fewer full-time employees) that
			 do not impose undue economic hardship for small businesses, including
			 dispensers with respect to which the study concluded has insufficient hardware
			 and software to conduct interoperable, electronic tracing of prescription drug
			 products at the package level; and</text>
					</subparagraph>
          <subparagraph id="H6FB990F8D79C4487BB27AA6207458C28">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">establishing a process by which a dispenser
			 may request a waiver from any such requirement.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H2E9D350FCB534CB78AC39DF489F8D7C8">
          <enum>(5)</enum>
          <header>Regulations</header>
          <text>In
			 issuing regulations to carry out this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
					<subparagraph id="H68684941F11341BBB0073D0724178314">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">issue a notice of proposed rulemaking that
			 includes a copy of the proposed rule;</text>
					</subparagraph>
          <subparagraph id="H733BD5622F284E39936CE3A6005F04BF">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">provide for a period of not less than 60
			 days for comments on the proposed rule; and</text>
					</subparagraph>
          <subparagraph id="H0168C2A6C16D4CCD9C1F5815995E6037">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">provide for an effective date of the final
			 rule that is 2 years after the date on which such final rule is
			 published.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H6D92507B4A4A48F9BC80D0F954F6DC73">
          <enum>(6)</enum>
          <header>Sunset</header>
          <text display-inline="yes-display-inline">The requirements regarding the provision
			 and receipt of transaction history and transaction statements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582
			 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>, shall cease
			 to be effective on the date on which the regulations issued under this section
			 are fully implemented.</text>
				</paragraph>
      </subsection>
      <subsection commented="no" id="H24B81CE6E1FB4D3987CFD9E2BCB8F321">
        <enum>(g)</enum>
        <header>Definitions</header>
        <text display-inline="yes-display-inline">In this section:</text>
				<paragraph commented="no" id="H94ABA3177C984E83B4E9E8D6B7FE1AFE">
          <enum>(1)</enum>
          <text display-inline="yes-display-inline">The terms defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581" proposed="true">section 581 of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>, shall have the
			 same meanings in this section as such terms are given in such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581" proposed="true">section
			 581</cato:entity-ref>.</text>
				</paragraph>
        <paragraph commented="no" id="H0A54556E02E94F3F8ABE39D35A9339B6">
          <enum>(2)</enum>
          <text>The term
			 <term>Secretary</term> means the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref>, acting
			 through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and Drugs</cato:entity-ref>.</text>
				</paragraph>
      </subsection>
    </section>
    <section id="HBC811089AEF040D7BD190C77C6C8F710">
      <enum>4.</enum>
      <header>National
			 standards for wholesale distributors</header>
			<subsection id="HB8818AFAB2C24D4AB571092F916C5DB5">
        <enum>(a)</enum>
        <header>Standards</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V">Chapter
			 V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/351">
              <cato:entity-ref entity-type="uscode" value="usc/21/351/etseq">21 U.S.C. 351 et seq.</cato:entity-ref>
            </external-xref>)</cato:entity> is
			 amended—</text>
				<paragraph id="H0CBAFED4AE0441098FF86887053FD248">
          <enum>(1)</enum>
          <text>in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503">section 503 of
			 such Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353">
                <cato:entity-ref entity-type="uscode" value="usc/21/353">21 U.S.C. 353</cato:entity-ref>
              </external-xref>)</cato:entity>, by striking <quote>(e)(1)(A)</quote> and all that
			 follows through <quote>(3) For purposes of this subsection and subsection
			 (d)—</quote> and inserting the following:</text>
					<quoted-block display-inline="no-display-inline" id="H480C5478B83A43B999F9DB88682FC897" style="OLC">
						<subsection id="H24B9E5BF3FDE48BA892A2684D46FDE15">
              <enum>(e)</enum>
              <text display-inline="yes-display-inline">For purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:d">subsection
				(d)</cato:entity-ref>—</text>
						</subsection>
            <after-quoted-block>;
				and</after-quoted-block>
          </quoted-block>
				</paragraph>
        <paragraph id="H40040074D979409BB3B458A100D12476">
          <enum>(2)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">subchapter H of
			 chapter V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>,
			 by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="HB7949EF6EF944B57A383F9A7625D4596" style="OLC">
						<section id="HA38ED815C32844B8AE887EAD9B077667">
              <enum>583.</enum>
              <header>National
				standards for wholesale distributors</header>
							<subsection commented="no" id="H0F700130E9F24198B419F7219014857D">
                <enum>(a)</enum>
                <header>Standards</header>
								<paragraph id="H1723955E76DD454DB2624B0B260F348B">
                  <enum>(1)</enum>
                  <header>In
				general</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish, by regulation, standards
				for the licensing of persons that make wholesale distributions.</text>
								</paragraph>
                <paragraph id="H6D4080E3BFF646FDA387DC3F753947F6">
                  <enum>(2)</enum>
                  <header>Requirements</header>
                  <text>The
				standards under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall, with respect to wholesale distributions,
				include requirements for—</text>
									<subparagraph id="HA5BD4EEABCEE41D6B42A1EC64A6B55BB">
                    <enum>(A)</enum>
                    <text>the storage and
				handling of drugs subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>, including facility
				requirements;</text>
									</subparagraph>
                  <subparagraph id="H222BB42A4FE2440ABB07549687CE3ECA">
                    <enum>(B)</enum>
                    <text>the establishment
				and maintenance of records of the distributions of such drugs;</text>
									</subparagraph>
                  <subparagraph commented="no" id="HEADAC412ED724824ABFA6650F0C7C3B1">
                    <enum>(C)</enum>
                    <text>the furnishing of
				a bond or other equivalent means of security in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:3" proposed="true">paragraph
				(3)</cato:entity-ref>;</text>
									</subparagraph>
                  <subparagraph id="H33BB70E01F7C4EC08E4168649B5C8E57">
                    <enum>(D)</enum>
                    <text>mandatory
				background checks and fingerprinting of facility managers or designated
				representatives;</text>
									</subparagraph>
                  <subparagraph id="H4B81C1D43174477299BC8F1A8784C6A7">
                    <enum>(E)</enum>
                    <text>the establishment
				and implementation of qualifications for key personnel;</text>
									</subparagraph>
                  <subparagraph id="H4CBF8DCDA3AB48C9B9A839D935EB4682">
                    <enum>(F)</enum>
                    <text>the mandatory
				physical inspection of any facility to be used in wholesale distribution within
				a reasonable timeframe from the initial application for licensure of the
				wholesale distributor; and</text>
									</subparagraph>
                  <subparagraph id="H8356D22D289846A29041436F0A2CC4E3">
                    <enum>(G)</enum>
                    <text>in accordance with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:5" proposed="true">paragraph (5)</cato:entity-ref>, the prohibition of certain persons from engaging in wholesale
				distribution.</text>
									</subparagraph>
                </paragraph>
                <paragraph commented="no" id="H475F8A911A564F2A9294A69F6944E527">
                  <enum>(3)</enum>
                  <header>Bond or other
				security</header>
                  <text>The requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:2/sp:C" proposed="true">paragraph (2)(C)</cato:entity-ref> shall provide
				for the following:</text>
									<subparagraph commented="no" id="H9622200E5D894BCB99CB35950F076A75">
                    <enum>(A)</enum>
                    <text>An applicant that
				is not a government-owned-and-operated wholesale distributor, for the issuance
				or renewal of a wholesale distributor license, shall submit a surety bond of
				$100,000 or other equivalent means of security acceptable to the applicable
				licensing authority.</text>
									</subparagraph>
                  <subparagraph commented="no" id="HC87EB280177A46888E664C0E4E6CB406">
                    <enum>(B)</enum>
                    <text>For purposes of
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the applicable licensing authority may accept a surety bond
				less than $100,000 if the annual gross receipts of the previous tax year for
				the wholesale distributor is $10,000,000 or less, in which case the surety bond
				may not be less than $25,000.</text>
									</subparagraph>
                  <subparagraph commented="no" id="HC38523EE47D648849176FE28C3274974">
                    <enum>(C)</enum>
                    <text>If a wholesale
				distributor can provide evidence that it possesses the required bond in a
				State, the requirement for a bond in another State is waived.</text>
									</subparagraph>
                </paragraph>
                <paragraph commented="no" id="H42DA2B6B412844F1B11329F7E5FB26C4">
                  <enum>(4)</enum>
                  <header>Inspections</header>
                  <text>To
				satisfy the inspection requirement under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:2/sp:F" proposed="true">paragraph (2)(F)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may
				conduct the inspection, or may accept an inspection by—</text>
									<subparagraph id="H2DA2032EADD24F4993A7C130A801555D">
                    <enum>(A)</enum>
                    <text>the government of
				the State in which the facility is located; or</text>
									</subparagraph>
                  <subparagraph id="H590D4747AA10472C9B443C9AE0135FD1">
                    <enum>(B)</enum>
                    <text>a third-party
				accreditation or inspection service approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="HD38D5E3706444729A7C48FFCC82A106F">
                  <enum>(5)</enum>
                  <header>Prohibited
				persons</header>
                  <text>The requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:2" proposed="true">paragraph (2)</cato:entity-ref> shall include
				requirements to prohibit a person from receiving or maintaining licensure for
				wholesale distribution if the person—</text>
									<subparagraph id="H78DC6CC7B3694993B41A5A55AC9FE126">
                    <enum>(A)</enum>
                    <text>has been convicted
				of any felony for conduct relating to wholesale distribution; any felony
				violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:i">section 301(i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:k">301(k)</cato:entity-ref>; or any felony violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1365">section 1365
				of title 18, United States Code</cato:entity-ref>, relating to prescription drug product
				tampering; or</text>
									</subparagraph>
                  <subparagraph id="HFA9945EE01FB4C5C9DFDA3DBB0532F77">
                    <enum>(B)</enum>
                    <text>has engaged in a
				pattern of violating the requirements of this section that presents a threat of
				serious adverse health consequences or death to humans.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection commented="no" id="HAACF8B231D7B468B8AEB88E99004A2A2">
                <enum>(b)</enum>
                <header>Reporting by
				licensed wholesale distributors</header>
								<paragraph commented="no" id="HA728712D9012424D81432929813C87A3">
                  <enum>(1)</enum>
                  <header>Annual
				report</header>
                  <text>Beginning not later than 1 year after the date of the
				enactment of this section, each person engaged in wholesale distribution in
				interstate commerce shall submit on an annual basis, and update as necessary, a
				report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> including—</text>
									<subparagraph commented="no" id="H9355644CECA1453891A4622621C1A627">
                    <enum>(A)</enum>
                    <text>the wholesale
				distributor’s name;</text>
									</subparagraph>
                  <subparagraph commented="no" id="H3A058C3A54D24F6EA8964F5574D43183">
                    <enum>(B)</enum>
                    <text>the wholesale
				distributor’s address;</text>
									</subparagraph>
                  <subparagraph commented="no" id="HCB6CD8B0C327493585C1D186FBEB9315">
                    <enum>(C)</enum>
                    <text>a listing of each
				State in which the wholesale distributor is licensed for wholesale
				distribution; and</text>
									</subparagraph>
                  <subparagraph commented="no" id="H31E4B91980A44DD991379FC47BF3F05C">
                    <enum>(D)</enum>
                    <text>any disciplinary
				actions taken by a State, the Federal Government, or a foreign government
				during the reporting period against the wholesale distributor.</text>
									</subparagraph>
                </paragraph>
                <paragraph commented="no" id="HE719FCE235DF4D60906688DB0EE47338">
                  <enum>(2)</enum>
                  <header>Posting on
				Internet</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall post on the public Internet Website
				of the Food and Drug Administration the name of each wholesale distributor, and
				the State in which each such distributor is licensed, based on reports under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
								</paragraph>
              </subsection>
              <subsection commented="no" id="HBAC994B5E620452492AF27A551B19BE0">
                <enum>(c)</enum>
                <header>Preservation of
				State authority</header>
                <text>This subchapter does not prohibit a State
				from—</text>
								<paragraph commented="no" id="H8CD0AE2009384EA1AA26858FE332FDCE">
                  <enum>(1)</enum>
                  <text>licensing
				wholesale distributors for the conduct of wholesale distribution activities in
				the State in accordance with this subchapter; and</text>
								</paragraph>
                <paragraph commented="no" id="HAD38D06D7FB84B23AE35E1721E4AAAFA">
                  <enum>(2)</enum>
                  <text>collecting fees
				from wholesale distributors in connection with such licensing,</text>
								</paragraph>
                <continuation-text commented="no" continuation-text-level="subsection">so long as the State does not
				require such licensure to the extent to which an entity is engaged in
				third-party logistics provider activities.</continuation-text>
              </subsection>
              <subsection id="HF830CA22396F4EE59900854FA5F43F6F">
                <enum>(d)</enum>
                <header>Definition</header>
                <text>In
				this section, the term <term>wholesale distribution</term> means the
				distribution of a drug subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref> to a person other than a
				consumer or patient, but does not include—</text>
								<paragraph id="H1FE84FCABA1345AA950AC1FED9AA6F51">
                  <enum>(1)</enum>
                  <text>intracompany
				distribution of any drug between members of an affiliated group (as defined in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1504/ss:a">
                      <external-xref legal-doc="usc" parsable-cite="usc/26/1504">section 1504(a)</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref>);</text>
								</paragraph>
                <paragraph id="HFAC31CECEF704B118EFBC5B96EC0104F">
                  <enum>(2)</enum>
                  <text>the distribution
				of a drug, or an offer to distribute a drug among hospitals or other health
				care entities which are under common control;</text>
								</paragraph>
                <paragraph id="HA67AA4B365674D699523745173DE9721">
                  <enum>(3)</enum>
                  <text>the distribution
				of a drug or an offer to distribute a drug for emergency medical reasons,
				including a public health emergency declaration pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:319">section 319 of the
				Public Health Service Act</cato:entity-ref>, except that a drug shortage not caused by a public
				health emergency shall not constitute such an emergency medical reason;</text>
								</paragraph>
                <paragraph id="H6C898FDCE1EE4532A0FCDF002B85BC03">
                  <enum>(4)</enum>
                  <text>dispensing of a
				drug pursuant to a valid prescription executed in accordance with sub<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section
				503(b)(1)</cato:entity-ref>;</text>
								</paragraph>
                <paragraph id="HEE9EE88AB57D40F5AD2B48A63FBFA935">
                  <enum>(5)</enum>
                  <text>the distribution
				of minimal quantities of drug by a licensed retail pharmacy to a licensed
				practitioner for office use;</text>
								</paragraph>
                <paragraph id="HF63888303ED64651B5891B4B3022529B">
                  <enum>(6)</enum>
                  <text>the distribution
				of a drug or an offer to distribute a drug by a charitable organization to a
				nonprofit affiliate of the organization to the extent otherwise permitted by
				law;</text>
								</paragraph>
                <paragraph id="H20AAAFA02E9C4E8AAD473D6AFB7F8451">
                  <enum>(7)</enum>
                  <text>the purchase or
				other acquisition by a dispenser, hospital, or other health care entity of a
				drug for use by such dispenser, hospital, or other health care entity;</text>
								</paragraph>
                <paragraph id="HC2294388D58C42988842D2AC5AF9F8A5">
                  <enum>(8)</enum>
                  <text>the distribution
				of a drug by the manufacturer of such drug;</text>
								</paragraph>
                <paragraph id="HB90C3A0490E446A3A04DEDC3CF0B39CD">
                  <enum>(9)</enum>
                  <text>the receipt or
				transfer of a drug by an authorized third-party logistics provider provided
				that such third-party logistics provider does not take ownership of the
				drug;</text>
								</paragraph>
                <paragraph id="HE67EFF2171EF4476B198624611A91B35">
                  <enum>(10)</enum>
                  <text>the transport of
				a drug by a common carrier, provided that the common carrier does not take
				ownership of the drug;</text>
								</paragraph>
                <paragraph id="HFDFF4BDEB2C94589B2E73A0F1E7BC55D">
                  <enum>(11)</enum>
                  <text>the distribution
				of a drug, or an offer to distribute a drug, by an authorized repackager that
				has taken ownership of the drug and repacked it in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:582/ss:e" proposed="true">section
				582(e)</cato:entity-ref>;</text>
								</paragraph>
                <paragraph id="HA1F8215D0A0E4D109181F5210791B6CE">
                  <enum>(12)</enum>
                  <text>saleable drug
				returns when conducted by a dispenser in accordance with section 203.23 of
				title 21, Code of Federal Regulations (or any successor regulation);</text>
								</paragraph>
                <paragraph commented="no" id="H8D79DF64DF7A4E0E96EFCB6E10854824">
                  <enum>(13)</enum>
                  <text>the distribution
				of a combination prescription drug product described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:20/sp:B/cl:xiii" proposed="true">section
				581(20)(B)(xiii)</cato:entity-ref>;</text>
								</paragraph>
                <paragraph id="H23B539339C0B4296B72C24617B528453">
                  <enum>(14)</enum>
                  <text>the distribution
				of a medical convenience kit described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:21/sp:B/cl:xiv" proposed="true">section 581(21)(B)(xiv)</cato:entity-ref>;</text>
								</paragraph>
                <paragraph id="HF090407DE470412786CE8A28C9281089">
                  <enum>(15)</enum>
                  <text>the distribution
				of an intravenous drug that, by its formulation, is intended for the
				replenishment of fluids and electrolytes (such as sodium, chloride, and
				potassium) or calories (such as dextrose and amino acids);</text>
								</paragraph>
                <paragraph id="HA8A1E6027C3B402E9D1FAAAC99550345">
                  <enum>(16)</enum>
                  <text>the distribution
				of an intravenous drug used to maintain the equilibrium of water and minerals
				in the body, such as dialysis solutions;</text>
								</paragraph>
                <paragraph id="H4F8F76625440448180429E4AB8DF287B">
                  <enum>(17)</enum>
                  <text>the distribution
				of a drug that is intended for irrigation or reconstitution, or sterile water,
				whether intended for such purposes or for injection;</text>
								</paragraph>
                <paragraph id="HC5FC34C5107D427094FF4649EF2EBA31">
                  <enum>(18)</enum>
                  <text>the distribution
				of compressed medical gas (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:21/sp:C" proposed="true">section 581(21)(C)</cato:entity-ref>); or</text>
								</paragraph>
                <paragraph id="H1E0C04450C144BD7A91C1D45D4EADECA">
                  <enum>(19)</enum>
                  <text>facilitating the
				distribution of a prescription drug product by providing administrative
				services, such as processing of orders and payments, without physical handling,
				distribution, or storage of a prescription drug product.</text>
								</paragraph>
              </subsection>
              <subsection id="H7CA2808BF663489E888E2AEFCB58B947">
                <enum>(e)</enum>
                <header>Effective
				date</header>
                <text>The standards required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall take effect
				not later than 2 years after the date of the enactment of this section. The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue the regulations required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a" proposed="true">subsection (a)</cato:entity-ref> not later than
				1 year after the date of the enactment of this
				Act.</text>
							</subsection>
            </section>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection id="H8E106183AC9945E4AEF573F662FE7763">
        <enum>(b)</enum>
        <header>Conforming
			 amendment</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:804/ss:a/p:5/sp:A">Section 804(a)(5)(A) of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/384">
              <cato:entity-ref entity-type="uscode" value="usc/21/384/a/5/A">21 U.S.C. 384(a)(5)(A)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by striking
			 <quote>503(e)(2)(A)</quote> and inserting <quote>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a" proposed="true">583(a)</cato:entity-ref>
          </quote>.</text>
			</subsection>
    </section>
    <section id="H02F1F3FBD44A4CEEB8AB35881F40C73A">
      <enum>5.</enum>
      <header>National
			 licensure standards for third-party logistics providers</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">Subchapter H of chapter V of the Federal
			 Food, Drug, and Cosmetic Act</cato:entity-ref>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:4" proposed="true">section 4</cato:entity-ref>, is further amended by
			 adding at the end the following:</text>
			<quoted-block id="H1521D8469A2F409BBEF0E8413BCC3D05" style="OLC">
				<section id="H7579125362464C348C24197617DC8CCF">
          <enum>584.</enum>
          <header>National
				licensure standards for third-party logistics providers</header>
					<subsection id="H5D714CDA506841A3B629162BA7EEFC88">
            <enum>(a)</enum>
            <header>License
				requirement</header>
            <text>No facility may engage in the activities of a
				third-party logistics provider in any State unless—</text>
						<paragraph id="H5A7BB524AD8247F69E69B97155BDF9AD">
              <enum>(1)</enum>
              <text>the facility is
				licensed—</text>
							<subparagraph id="HB4F32939E84D4EF8B4D2CECBD64AD6ED">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">by the State from which the drug is
				distributed by the third-party logistics provider in accordance with a
				qualified licensing program, if the State has such a program; or</text>
							</subparagraph>
              <subparagraph id="HBFED22D5F72B4B29A33B338367AD885D">
                <enum>(B)</enum>
                <text>by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				under this section, if the State from which the drug is distributed does not
				have such a program; and</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H256015086D494ACFA079177BFEC39355">
              <enum>(2)</enum>
              <text display-inline="yes-display-inline">if the drug is distributed interstate and
				the facility is not licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:a/p:1/sp:B" proposed="true">paragraph (1)(B)</cato:entity-ref>, registers
				with the State into which the drug is distributed if such State requires such
				registration.</text>
						</paragraph>
          </subsection>
          <subsection commented="no" id="H5D0435789EE74FF3B6FE973710F881B1">
            <enum>(b)</enum>
            <header>Reporting by
				licensed third-Party logistics providers</header>
						<paragraph commented="no" id="HE1C9124166BC423FB54462E1B83ABAFC">
              <enum>(1)</enum>
              <header>Annual
				report</header>
              <text>Beginning not later than 1 year after the date of the
				enactment of this section, each facility engaged in the activities of a
				third-party logistics provider shall submit on an annual basis, and update as
				necessary, a report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> including—</text>
							<subparagraph commented="no" id="H9183B66366194F62ADCB162DD19DCE1C">
                <enum>(A)</enum>
                <text>the facility’s
				name;</text>
							</subparagraph>
              <subparagraph commented="no" id="H37E81A476D60458BA34F13598BAB31CE">
                <enum>(B)</enum>
                <text>the facility’s
				address;</text>
							</subparagraph>
              <subparagraph commented="no" id="HC53B3B920A534B9DBCC145AC7347A12D">
                <enum>(C)</enum>
                <text>a listing of each
				jurisdiction (whether State or Federal) in which the facility is licensed for
				third-party logistics provider activities; and</text>
							</subparagraph>
              <subparagraph commented="no" id="HD189FA1E2EA4406EB0C4C722C7BA0073">
                <enum>(D)</enum>
                <text>any disciplinary
				actions taken by a State or Federal licensing authority during the reporting
				period against the facility.</text>
							</subparagraph>
            </paragraph>
            <paragraph commented="no" id="H32CA3CC203134A1B838A0D7A54D2D57E">
              <enum>(2)</enum>
              <header>Posting on
				Internet</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				post on the public Internet Website of the Food and Drug Administration the
				name of each third party logistics provider, and each jurisdiction (whether
				State or Federal) in which the provider is licensed, based on reports under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection commented="no" id="HCF409F783A294F62A34421D7C3088E5D">
            <enum>(c)</enum>
            <header>Preservation of
				State authority</header>
            <text>This subchapter does not prohibit a State
				from—</text>
						<paragraph commented="no" id="H3EE7B1D3D3444E29B9C95604A21B2566">
              <enum>(1)</enum>
              <text>licensing
				third-party logistic providers for the conduct of third-party logistics
				provider activities in the State in accordance with this subchapter; and</text>
						</paragraph>
            <paragraph commented="no" id="HB8A139F41CAD4C5A8544E4ADAD199626">
              <enum>(2)</enum>
              <text>collecting fees
				from third-party logistics providers in connection with such licensing,</text>
						</paragraph>
            <continuation-text commented="no" continuation-text-level="subsection">so long as the State does not
				require such licensure to the extent to which an entity is engaged in wholesale
				distribution.</continuation-text>
          </subsection>
          <subsection id="H123641421A634071BFEA6500E472767A">
            <enum>(d)</enum>
            <header>Costs</header>
						<paragraph id="HA582A53537FC44AD923283AC403D5447">
              <enum>(1)</enum>
              <header>Authorized
				licensure fees</header>
              <text>In the case of a facility engaging in the
				activities of a third-party logistics provider licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under
				this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess and collect a reasonable fee in an
				amount equal to the costs to the Federal Government of establishing and
				administering the licensure program established, and conducting period
				inspections, under this section.</text>
						</paragraph>
            <paragraph id="HB49D15DDA1664B1CBF47579D911A2A5D">
              <enum>(2)</enum>
              <header>Adjustment</header>
              <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall adjust the amount of the fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> on an annual
				basis, if necessary, to generate an amount of revenue equal to the costs
				referred to in such paragraph.</text>
						</paragraph>
            <paragraph id="HF8D6E26AAD714F4A9F094875A4D1DCC2">
              <enum>(3)</enum>
              <header>Availability</header>
              <text display-inline="yes-display-inline">Fees assessed and collected under this
				subsection shall be available for obligation only to the extent and in the
				amount provided in advance in appropriations Acts. Such fees shall remain
				available until expended.</text>
						</paragraph>
          </subsection>
          <subsection id="H18060B4655E94063A16CC576DC968A78">
            <enum>(e)</enum>
            <header>License
				regulations</header>
						<paragraph id="H88903611E34441618A21C24FB4434315">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish, by regulation, standards,
				terms, and conditions for licensing persons to engage in third-party logistics
				provider activities.</text>
						</paragraph>
            <paragraph id="H5945E81FD9A44FCAB815A318C1FAA0CE">
              <enum>(2)</enum>
              <header>Content</header>
              <text>The
				regulations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:e/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall—</text>
							<subparagraph id="HE29F50FF6BD949DF8B691214A467D2DD">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">include standards relating to eligibility
				for, and revocation and reissuance of, licenses;</text>
							</subparagraph>
              <subparagraph id="H78D3F6C7B2F2451184A8DD5EAD40A200">
                <enum>(B)</enum>
                <text>establish a
				process by which the applicable licensing authority will, upon request by a
				third-party logistics provider that is accredited by a third-party
				accreditation program approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, issue a license to the
				provider;</text>
							</subparagraph>
              <subparagraph id="HFA2681AE7146418597E4BCADF3B622F6">
                <enum>(C)</enum>
                <text>establish a
				process by which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a license to a third-party logistics
				provider if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> is not able to approve a third-party accreditation
				program because no such program meets the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>’s requirements necessary
				for approval of such a third-party accreditation program;</text>
							</subparagraph>
              <subparagraph id="HA06FFB457508460B9C25C375C16D89DC">
                <enum>(D)</enum>
                <text>require that the
				third-party logistics provider comply with storage practices, as determined by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, at the provider’s facilities, including—</text>
								<clause id="HF6DBADD6855E4A64BB5D557293D1E4E2">
                  <enum>(i)</enum>
                  <text>maintaining access
				to warehouse space of suitable size to facilitate safe operations, including a
				suitable area to quarantine suspect prescription drug product;</text>
								</clause>
                <clause id="HC9FCD03E3CF04D49BC613EE5D742F435">
                  <enum>(ii)</enum>
                  <text>maintaining
				adequate security; and</text>
								</clause>
                <clause id="HBCCCA9C6951C40A1B9156FC157AC60FE">
                  <enum>(iii)</enum>
                  <text>having written
				policies and procedures to—</text>
									<subclause id="H2674C2B51ABC438880507BEE11578B5B">
                    <enum>(I)</enum>
                    <text>address receipt,
				security, storage, inventory, shipment, and distribution of a prescription drug
				product;</text>
									</subclause>
                  <subclause id="H397268090C204781A63409FBA07FC262">
                    <enum>(II)</enum>
                    <text>identify, record,
				and report confirmed losses or thefts in the United States;</text>
									</subclause>
                  <subclause id="H5EB72E436BF443778C1E76DC1B5D15E2">
                    <enum>(III)</enum>
                    <text>correct errors
				and inaccuracies in inventories;</text>
									</subclause>
                  <subclause id="HCAD7A2F0AC30476DA2642618C41ED24F">
                    <enum>(IV)</enum>
                    <text>provide support
				for manufacturer recalls;</text>
									</subclause>
                  <subclause id="H859D95E180AB4631B548B13625AE17AC">
                    <enum>(V)</enum>
                    <text>prepare for,
				protect against, and address any reasonably foreseeable crisis that affects
				security or operation at the facility, such as a strike, fire, or flood;</text>
									</subclause>
                  <subclause id="H08CE36D25FEE4972B3FD52EDD79CE59E">
                    <enum>(VI)</enum>
                    <text>ensure that any
				expired prescription drug product is segregated from other prescription drug
				products and returned to the manufacturer or repackager or destroyed;</text>
									</subclause>
                  <subclause id="H8C4A7B3687F746E08671C574AFAB8E1F">
                    <enum>(VII)</enum>
                    <text>maintain the
				capability to electronically trace the receipt and outbound distribution of a
				prescription drug product, and supplies and records of inventory; and</text>
									</subclause>
                  <subclause id="HE72CEF93AA6D4A4281BF3C70E1706EEC">
                    <enum>(VIII)</enum>
                    <text>quarantine or
				destroy a suspect prescription drug product if directed to do so by the
				respective manufacturer, wholesale distributor, dispenser, or an authorized
				government agency;</text>
									</subclause>
                </clause>
              </subparagraph>
              <subparagraph id="H674EFF673AC643DF81BFEEC2CC08AD49">
                <enum>(E)</enum>
                <text>provide for
				periodic inspection, as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, of such facility warehouse
				space to ensure compliance with this section;</text>
							</subparagraph>
              <subparagraph id="H01C9A1B5658748C58585515629DB8C97">
                <enum>(F)</enum>
                <text>prohibit a
				facility from having as a manager or designated representative anyone convicted
				of any felony violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:i">section 301(i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:k">301(k)</cato:entity-ref> or any felony violation of
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1365">
                    <external-xref legal-doc="usc" parsable-cite="usc/18/1365">section 1365</external-xref> of title 18, United States Code</cato:entity-ref>, relating to prescription drug
				product tampering;</text>
							</subparagraph>
              <subparagraph id="H3432EDEC1C1D48688F0EE587C70F2530">
                <enum>(G)</enum>
                <text>perform mandatory
				background checks of the provider’s facility managers or designated
				representatives of such managers;</text>
							</subparagraph>
              <subparagraph id="HF5F0F5B2390E49B5B6FFCE8D25885289">
                <enum>(H)</enum>
                <text>require a
				third-party logistics provider to provide to the applicable licensing
				authority, upon the authority’s request, a list of all prescription drug
				product manufacturers, wholesale distributors, and dispensers for whom the
				third-party logistics provider provides services at the provider’s facilities;
				and</text>
							</subparagraph>
              <subparagraph id="H1859F983DD2240F695E9ECDB5E7AD4E9">
                <enum>(I)</enum>
                <text>include procedures
				under which any third-party logistics provider license—</text>
								<clause id="H88875B8EA32346108396949AA81DB959">
                  <enum>(i)</enum>
                  <text>will expire on the
				date that is 3 years after issuance of the license; and</text>
								</clause>
                <clause id="H9168150D057146F9B2F5FB471DACFA28">
                  <enum>(ii)</enum>
                  <text>may be renewed
				for additional 3-year periods.</text>
								</clause>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="H162350C63FFC4294AA7D7E4B8CDFE15D">
            <enum>(f)</enum>
            <header>Validity of
				license</header>
            <text>A license issued under this section shall remain valid as
				long as such third-party logistics provider remains accredited by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, subject to renewal under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:d" proposed="true">subsection (d)</cato:entity-ref>. If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds that
				the third-party accreditation program demonstrates that all applicable
				requirements for licensure under this section are met, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				issue a license under this section to a third-party logistics provider
				receiving accreditation.</text>
					</subsection>
          <subsection id="H993CE19AFF644291A3CC138B8DF7ECF1">
            <enum>(g)</enum>
            <header>Qualified
				licensing program defined</header>
            <text>In this section, the term
				<term>qualified licensing program</term> means a program meeting the
				requirements of this section and the regulations thereunder.</text>
					</subsection>
          <subsection id="H84E953BC0D8343D888A8BDF37D7C3E77">
            <enum>(h)</enum>
            <header>Effective
				date</header>
            <text>The requirements of this section shall take effect not later
				than 1 year after the date of the enactment of this section. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall issue the regulations required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:d" proposed="true">subsection (d)</cato:entity-ref> not later than 180 days
				after the date of the enactment of this
				section.</text>
					</subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="HBBE033AA9EFC4648B1362CE5C0B58FBA">
      <enum>6.</enum>
      <header>Penalties</header>
			<subsection id="HF68D125E62B94D3297DE48CA93F67B2B">
        <enum>(a)</enum>
        <header>Prohibited
			 acts</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:t">Section 301(t) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>
			 (<external-xref legal-doc="usc" parsable-cite="usc/21/331">
              <cato:entity-ref entity-type="uscode" value="usc/21/331/t">21 U.S.C. 331(t)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended—</text>
				<paragraph id="H1DD64BB55DAA48CA8FA78E094152AF81">
          <enum>(1)</enum>
          <text>by striking
			 <quote>or</quote> after <quote>the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:d">section 503(d)</cato:entity-ref>
            </quote>;
			 and</text>
				</paragraph>
        <paragraph id="H5AEFBCF9DC334605B0492CA5EF878DFD">
          <enum>(2)</enum>
          <text>by striking
			 <quote>or the distribution of drugs in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref> or the
			 failure to otherwise comply with the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref>
            </quote> and
			 inserting <quote>the failure to comply with any requirement of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref>,
			 engaging in the wholesale distribution of a drug in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref> or
			 the failure to otherwise comply with the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>, or
			 engaging in the activities of a third-party logistics provider in violation of
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">section 584</cato:entity-ref> or the failure to otherwise comply with the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">section
			 584</cato:entity-ref>
            </quote>.</text>
				</paragraph>
      </subsection>
      <subsection id="H0E2C96951C284DB4BEAEF0FA819A1CB0">
        <enum>(b)</enum>
        <header>Enhanced penalty
			 for knowing unlicensed activities</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:303/ss:b/p:1/sp:D">Section 303(b)(1)(D) of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/333">
              <cato:entity-ref entity-type="uscode" value="usc/21/333/b/1/D">21 U.S.C. 333(b)(1)(D)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by
			 striking <quote>503(e)(2)(A)</quote> and inserting <quote>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">583</cato:entity-ref> or
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">584</cato:entity-ref>
          </quote>.</text>
			</subsection>
      <subsection id="HFEE5E6E15B794CD49EADCD6B8007895C">
        <enum>(c)</enum>
        <header>Misbranding</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502">Section
			 502 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/352">
              <cato:entity-ref entity-type="uscode" value="usc/21/352">21 U.S.C. 352</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by
			 adding at the end the following:</text>
				<quoted-block id="H5FF81C8E35AF4CE58502E535970EF4B8" style="OLC">
					<subsection id="H05AEBD71A57349A8916F7BB08EF29A2E">
            <enum>(bb)</enum>
            <text>If it is a drug
				and it fails to bear a prescription drug product identifier as required by
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section
				582</cato:entity-ref>.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
    </section>
    <section id="HB08D8528E49B4FF2AF7AFB4085BBE032">
      <enum>7.</enum>
      <header>Uniform national
			 policy</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">Subchapter H of chapter
			 V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:5" proposed="true">section 5</cato:entity-ref>, is
			 further amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H256948BDD0954487B97FC658724A87CE" style="OLC">
				<section id="HB417178AB6DA4D079AA2929751FC46F8">
          <enum>585.</enum>
          <header>Uniform
				national policy</header>
					<subsection id="H93264D2681504AFF869624FE647452DE">
            <enum>(a)</enum>
            <header>Preemption of
				State prescription drug product tracing and other
				requirements</header>
            <text>Beginning on the date of the enactment of the
				<short-title>
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of
				2013</cato:entity-ref>
              </short-title>, no State or political subdivision of a State may establish
				or continue in effect any requirements for tracing drugs through the
				distribution system (including any requirements with respect to paper or
				electronic pedigrees, track and trace, statements of distribution history,
				transaction history, or transaction statements, or verification, investigation,
				disposition, alerts, or recordkeeping relating to the pharmaceutical
				distribution supply chain system) that—</text>
						<paragraph id="H65FBD38CC15146F7B3A0B732F7E9488F">
              <enum>(1)</enum>
              <text>are inconsistent
				with, more stringent than, or in addition to any requirements applicable under
				this Act; or</text>
						</paragraph>
            <paragraph id="H9419AB6F57C6495AB75343DF39E1F7AF">
              <enum>(2)</enum>
              <text>are inconsistent
				with any applicable waiver, exception, or exemption issued by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a" proposed="true">section 582(a)</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection id="HD10BC700406841F28795CFC293911046">
            <enum>(b)</enum>
            <header>Standards or
				licensure</header>
						<paragraph id="H87466B1875E247BC8D2FEA6A3DF2681E">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>Beginning on the date of the enactment of
				<short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of
				2013</cato:entity-ref>
                </short-title>, no State or political subdivision of a State may establish
				or continue any standards, requirements, or regulations with respect to
				wholesale drug distributor or third-party logistics provider licensure which
				are inconsistent with, less stringent than, in addition to, or more stringent
				than, the standards and requirements under this Act.</text>
						</paragraph>
            <paragraph id="H319B123124CF4E84A2DDCAF5B99B71B2">
              <enum>(2)</enum>
              <header>Licensing
				fees</header>
              <text display-inline="yes-display-inline">
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:585/ss:b/p:1" proposed="true">Paragraph (1)</cato:entity-ref> does not
				affect the authority of a State to collect fees from wholesale drug
				distributors or third-party logistics providers in connection with State
				licensing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">584</cato:entity-ref> pursuant to a licensing program meeting the
				requirements of such sections.</text>
						</paragraph>
            <paragraph id="HB6F1BCCC4F2B411F8E7A6F8448898385">
              <enum>(3)</enum>
              <header>Enforcement,
				suspension, and revocation of licenses</header>
              <text display-inline="yes-display-inline">Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:585/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>, a
				State—</text>
							<subparagraph id="HD86BF346F3EB4A1A99B1D0343775652F">
                <enum>(A)</enum>
                <text>may take
				administrative action, including fines, to enforce a licensure requirement
				promulgated by the State in accordance with this Act;</text>
							</subparagraph>
              <subparagraph id="HD70EEFCBC56E421F8AB16B396302B7DF">
                <enum>(B)</enum>
                <text>may provide for
				the suspension or revocation of licenses issued by the State for violations of
				the laws of such State;</text>
							</subparagraph>
              <subparagraph id="H8F39809BA65E4F4B878305D1ED91E782">
                <enum>(C)</enum>
                <text>upon conviction of
				a person for a violation of Federal, State, or local controlled substance laws
				or regulations, may provide for fines, imprisonment, or civil penalties;
				and</text>
							</subparagraph>
              <subparagraph commented="no" id="HAE983814120C4A38B644C5B6962613AA">
                <enum>(D)</enum>
                <text>may regulate
				activities of entities licensed pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">584</cato:entity-ref> in a manner that
				is consistent with the provisions of this
				subchapter.</text>
							</subparagraph>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H3AA75D01CEC44FD3822CECB9C38A4019">
      <enum>8.</enum>
      <header>Electronic
			 labeling requirement</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f">Section
			 502(f) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/352">
            <cato:entity-ref entity-type="uscode" value="usc/21/352/f">21 U.S.C. 352(f)</cato:entity-ref>
          </external-xref>)</cato:entity> is
			 amended by adding at the end the following new sentence: <quote>Required
			 labeling, other than immediate container or carton labels, for a drug may be
			 made available by manufacturers and distributors solely by electronic means,
			 provided that the labeling complies with all applicable requirements of law and
			 the manufacturer or distributor, as applicable, affords health care
			 professionals and authorized dispensers (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581" proposed="true">section 581</cato:entity-ref>) the
			 opportunity to request the labeling in paper form, and after such request,
			 promptly provides the requested information without additional cost.</quote>.</text>
		</section>
  </legis-body>
</bill>
</doc>